Mitochondrial Permeability Regulates Cardiac Graft Ischemia-Reperfusion Injury and Allograft Rejection by Qamar, Adnan
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
2-4-2020 1:00 PM 
Mitochondrial Permeability Regulates Cardiac Graft Ischemia-
Reperfusion Injury and Allograft Rejection 
Adnan Qamar 
The University of Western Ontario 
Supervisor 
Zhang, Zhuxu 
The University of Western Ontario Co-Supervisor 
Jevnikar, Anthony 
The University of Western Ontario 
Graduate Program in Pathology and Laboratory Medicine 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Adnan Qamar 2020 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
Recommended Citation 
Qamar, Adnan, "Mitochondrial Permeability Regulates Cardiac Graft Ischemia-Reperfusion Injury and 
Allograft Rejection" (2020). Electronic Thesis and Dissertation Repository. 6833. 
https://ir.lib.uwo.ca/etd/6833 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
 
ii 
 
ABSTRACT 
The clinical relevance of ischemia-reperfusion injury (IRI) in the context of organ 
transplantation is well-established. IRI is associated with various forms of programmed cell 
death (PCD), of which necroptosis is particularly significant. Necroptosis is an inflammatory 
form of PCD that promotes alloimmunity and adversely affects allograft viability and function. 
We have recently shown the role of cyclophilin D (CypD), a critical mediator of mitochondrial 
permeability transition pore (mPTP) formation, in necroptosis. In this study, we investigated 
the downstream mechanism of hypoxia/reoxygenation-induced necroptosis and the effect of 
CypD inhibition in mitigating IRI-induced allograft injury and the subsequent alloimmune 
response in a clinically relevant model of cardiac transplantation. Our data indicate that 
inhibition of caspases during cold hypoxia-reoxygenation injury decreases apoptosis but 
increases necroptosis and that inhibition of CypD attenuates hypoxia/reoxygenation-induced 
necroptosis (n=3; p≤0.001). Interestingly, we found that hypoxia/reoxygenation-induced 
necroptosis involves apoptosis-inducing factor (AIF) translocation to the nucleus and that AIF 
silencing also attenuates hypoxia/reoxygenation-induced necroptosis (n=3; p≤0.001). Our in 
vivo studies confirm that CypD deficiency in ischemia-treated donor hearts mitigates IRI and 
allograft rejection (n=8; p=0.008). Our findings suggest that CypD inhibition following 
transplantation substantially attenuates necroptosis and mitigates allograft injury and the 
subsequent alloimmune response. Our data also indicate that AIF may be the downstream 
effector molecule that executes IRI-induced DNA damage in necroptosis. As such, targeting 
mitochondrial permeability may be a plausible approach in formulating therapeutic strategies 
aimed at improving allograft viability and function. 
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LAY SUMMARY  
Organ transplantation is essential for patients with end-stage organ disease. However, 
the procedure itself carries its own set of risks. One of the most pertinent risks is damage to the 
donor organ after its blood supply is cut off. This type of injury is associated with cell death 
and is called ischemic injury. It may be severe enough to render the donor organ unusable. 
Despite stringent protocols and guidelines for organ procurement, preservation and 
transportation, current strategies aimed at reducing ischemic injury are insufficient. Therefore, 
targeting cell death pathways in ischemic injury may be a better approach. Before such 
strategies can be developed, a thorough understanding of the cell death pathways in ischemic 
injury is required. In this study, we investigated a type of cell death called necroptosis. 
Necroptosis is a severe form of cell death that triggers the recipient's immune response against 
the donor organ. Hence, inhibiting necroptosis can help prolong donor organ survival 
following transplantation.  
Although necroptosis is involved in ischemic injury, the precise cellular mechanism(s) 
involved are not yet clear. According to recent research, a specialized cellular structure called 
mitochondrion that generates the cells' energy may be involved in necroptosis. Our data from 
this study indicate that mitochondrial components called 'Cyclophilin D' and 'Apoptosis-
Inducing Factor' play essential roles in necroptosis. We used pharmacological agents and 
genetic engineering techniques to inhibit the function of Cyclophilin D and Apoptosis-
Inducing Factor in individual cells and found that it protects against ischemic injury. We then 
extended our findings to an experiment simulating real-life conditions using mice hearts. We 
found that inhibiting Cyclophilin D and Apoptosis-Inducing Factor provides protection against 
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ischemic injury and helps promote donor heart survival. We hope to extend our findings to 
clinical studies and believe that our research will make the organ transplantation process better. 
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Chapter 1 
INTRODUCTION 
1.1 – Current Challenges in Cardiac Transplantation 
Congestive heart failure (CHF) is a significant public healthcare burden and affects 
37.7 million people worldwide [1, 2]. Common underlying causes of CHF include coronary 
artery disease, valvular dysfunction, cardiac arrhythmias, cardiomyopathy and congenital heart 
disease [1, 3]. The prevalence of CHF is predicted to rise further because of improvements in 
the clinical management of CHF patients, an increase in predisposing conditions (diabetes, 
hypertension), and population expansion and ageing [4, 5]. Despite marked improvements in 
medical therapy and mechanical circulatory support devices, cardiac transplantation is the 
preferred treatment option for unresponsive, end-stage CHF patients [6, 7, 8]. Compared to 
end-stage CHF patients on optimal medical and device therapy, transplant recipients have 
improved physical function, enhanced quality of life and prolonged survival [7, 8].  
Advances in human leukocyte antigen (HLA) matching, biopsy procedures, surgical 
techniques, and post-transplantation immunosuppressive protocols have increased the 1-year 
survival rate of patients undergoing cardiac transplantation to ~90% [7, 8, 9]. However, various 
limitations and challenges still exist. Postoperative management of patients undergoing cardiac 
transplantation is challenging. It includes monitoring for and addressing numerous 
complications with potentially significant impact on patient morbidity and mortality. These 
include graft failure/dysfunction (primary and late), allograft rejection, cardiac allograft 
vasculopathy, and adverse effects related to chronic immunosuppressive drugs (malignancy, 
infection) [7, 8, 10]. Despite the marked improvement in the 1-year survival rates, 
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complications related to chronic immunosuppression, chronic rejection and late graft failure 
are significant obstacles to long-term survival [7, 8, 10, 11]. Currently, the successful 
management of these significant post-transplantation complications is limited, and a thorough 
understanding of these conditions needs to be developed for improving long-term graft survival 
and function [7, 8, 10]. 
1.2 – Ischemia-Reperfusion Injury in Organ Transplantation 
Ischemia-reperfusion injury (IRI) is an inevitable consequence of organ transplant 
procedure (Figure 1) that can have life-threatening consequences in the immediate 
postoperative period, such as primary graft failure or dysfunction. IRI has also been shown to 
have deleterious long-term effects on graft survival and can contribute to graft rejection (Figure 
3) [4, 8, 12].  
1.2.1 – Pathophysiology of Ischemia Injury – Ischemia occurs with the cessation of arterial 
blood flow during organ procurement. It is a period of insufficient oxygen and nutrients supply 
that disrupts the electron transport chain (ETC) and oxidative phosphorylation, which induces 
anaerobic metabolism [13, 14]. This ultimately leads to the depletion of adenosine triphosphate 
(ATP) and profoundly affects cellular homeostasis. Failure of ATP-dependent membrane 
pumps such as the Na+/K+ ATPase pump leads to intracellular sodium overload, causing 
cellular edema, followed by cell swelling and altered ionic composition [13, 15]. Potassium 
ions move out of the cell while calcium ions accumulate within the cytoplasm due to reduced 
extracellular efflux by Ca2+ pumps and limited uptake by the endoplasmic reticulum (ER). The 
accumulation of intracellular calcium activates calcium-dependent proteases (e.g., calpains) 
and phospholipases, which results in injury to various cellular components [13, 14, 15, 16]. 
Anaerobic metabolism leads to lactic acid accumulation, intracellular acidosis and decreased 
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activity of many cellular enzymes. ATP depletion and cellular edema also result in detachment 
of the ribosomes from the rough ER (RER) and disruption of the cell’s protein-synthesizing 
machinery [13, 14, 15, 17]. Ionic and metabolic alterations can be reversed; however, once 
there is damage to the plasma membrane, lysosomes and mitochondria, irreversible widespread 
cellular injury occurs, and cell death follows (Figure 2) [13, 18]. 
1.2.2 – Pathophysiology of Reperfusion Injury – Although the restoration of blood is 
imperative to limit the degree of ischemic injury, it can have detrimental consequences. Injury 
induced by the restoration of blood supply is called reperfusion injury and occurs following 
reimplantation of the donor organ into the recipient. Reperfusion injury can damage previously 
unaffected cells and exacerbate injury caused by ischemia [13, 18]. Due to dysfunctional ETC 
activity and impaired cellular/mitochondrial enzymes, incoming oxygen is incompletely 
reduced and results in the generation of reactive oxygen species (ROS) [13, 14, 17]. ROS 
contribute to oxidative stress and avidly attack many biological molecules, including proteins, 
lipids, and nucleic acids [13, 17, 18, 19]. ROS-mediated cellular damage is exacerbated by the 
reduced antioxidant and ROS scavenging capacity of the cell. Restoration of blood flow further 
increases the intracellular accumulation of calcium ions transiently. The excess calcium ions 
are transported into the mitochondrial matrix by the mitochondrial Ca2+ uniporter [13, 17, 18]. 
Along with ROS, the excess calcium may induce the formation of the mitochondrial 
permeability transition pore (mPTP), which disrupts the proton motive force (PMF) and the 
mitochondrial transmembrane potential (ΔΨm) causing further depletion of ATP [13, 17, 20]. 
mPTP formation also leads to augmented osmotic pressure within the mitochondria, followed 
by mitochondrial swelling and rupture, releasing various mediators involved in cell death 
pathways (Figure 2) [13, 20].  
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1.2.3 – IRI-Associated Inflammatory Response – The pathological changes induced by IRI 
trigger a non-specific inflammatory response that contributes to the immunogenicity of the 
allograft and adversely affects allograft survival and function [21, 22]. This inflammatory 
response is initiated and perpetuated by ROS-mediated cell damage that alters several 
endogenous molecules. The altered molecules are called damage-associated molecular patterns 
(DAMPs) and include extracellular ATP, DNA fragments, uric acid (DNA breakdown 
product), heat shock proteins, heparan sulphate, and many others [21, 23, 26]. DAMPs are 
recognized by cellular pattern recognition receptors (PRRs) present on circulating leukocytes, 
endothelial cells, and epithelial cells [21, 26]. Ligation of PRRs activates the cytoplasmic 
protein called NLR Family Pyrin Domain Containing 3 (NLRP3), which in turn assembles a 
multiprotein cytosolic complex called the inflammasome. The inflammasome recruits and 
activates caspase-1, which processes various proinflammatory cytokines, including potent 
inflammatory mediators such as interleukins-1β (IL-1β) and -18 (IL-18) [21, 24, 25]. The 
engagement of PRRs, particularly toll-like receptors 2 and 4 (TLR-2 and 4), by DAMPs also 
activates nuclear factor-kappa B (NF-κB), a transcription factor that translocates to the nucleus 
and upregulates the expression of several proinflammatory cytokines and chemokines [21, 26]. 
The important upregulated proinflammatory cytokines include tumor necrosis factor-alpha 
(TNFα), interferon-gamma (IFNγ), IL-1, and IL-6, while the important chemokines include 
IL-8 and monocyte chemoattractant protein 1 (MCP-1). These chemokines belong to the C-X-
C (e.g., IL-8) and C-C chemokine (e.g., MCP-1) groups and are secreted by leukocytes and 
endothelial cells. The expression of proinflammatory cytokines and chemokine signaling 
promotes leukocyte infiltration and the activation of the complement system, thereby initiating 
the innate immune response [21, 26, 27].  
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All cells of the innate immune system express PRRs and are capable of sensing 
DAMPs; however, neutrophils and monocytes are principally responsible for acute 
inflammatory injury associated with IRI [21, 28, 29]. Neutrophils are the first leukocytes to 
infiltrate the site of injury. DAMPs and IL-8 from resident tissue macrophages, dendritic cells, 
and endothelial cells serve as potent neutrophil chemokines [21, 28]. Neutrophil-mediated graft 
injury involves the production and release of proteases, hydrolytic enzymes, neutrophil 
extracellular traps (NETs), and ROS [21, 30]. Moreover, in the presence of TNFα, neutrophils 
release various proinflammatory cytokines and chemokines that recruit additional leukocytes, 
including monocytes [21, 28]. Once recruited to the site of injury, monocytes differentiate into 
macrophages and can undergo the proinflammatory M1 or the anti-inflammatory M2 
polarization. TNFα and IFNγ stimulation and engagement of macrophage PRRs, particularly 
TLR2 and TLR4, by DAMPs promote M1 polarization [21, 31, 32, 33, 34]. Activated M1 
macrophages produce ROS and several proinflammatory cytokines like IL-1, IL-6, IL-17, IL-
23, TNFα, and IFNγ that mediate graft injury via diverse pathways, including the induction of 
programmed cell death pathways [35, 36, 37, 38, 39]. Macrophage recruitment also results in 
significant injury to the microvasculature and activation of the adaptive alloimmune responses 
[21, 31, 32]. Natural Killer (NK) cells have also been shown to play crucial roles in mediating 
acute and chronic allograft injury. Several studies have shown that NK cells are capable of 
'directly' lysing allograft endothelial and epithelial cells [40, 41]. NK cells can also 'indirectly' 
induce cellular death in the allograft by enhancing cellular and humoral alloimmune responses. 
NK cell-mediated allograft injury is significant and can occur even in the presence of T cell 
tolerance but remains an overlooked aspect of the immunosuppressive therapeutic strategies 
aimed at inducing allograft tolerance [40, 41, 42, 43, 44]. 
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1.2.4 – Role of Endothelial Cells in IRI and Associated Inflammatory Response – Endothelial 
cells play a crucial role in the inflammatory response associated with IRI. Leukocyte 
recruitment at the site of injury involves ‘endothelial activation’ – a process that induces a 
series of changes in the endothelial cells that facilitate their interaction with leukocytes [45, 
46]. TNFα, IL-1, and IL-6 upregulate the expression of adhesion molecules on the surface of 
endothelial cells via the activation of the NF-κB pathway [46, 47, 48]. The upregulated 
adhesion molecules include selectins (e.g., E-selectin and P-selectin), intercellular adhesion 
molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). Surface 
glycoproteins on activated leukocytes called integrins [e.g., leukocyte function-associated 
antigen-1 (LFA-1) and macrophage-1 antigen (Mac-1)] serve as ligands for endothelial cell 
adhesion molecules and mediate leukocyte adhesion to the endothelium. This is followed by 
leukocyte transmigration through the endothelium, which is aided by the adhesion molecule 
platelet endothelial cell adhesion molecule-1 (PECAM-1), and infiltration into the graft tissue 
along a chemokine gradient [21, 45, 46, 47, 48, 49].  
Endothelial activation can lead to ‘endothelial dysfunction’ if the inflammatory injury 
associated with IRI is severe, as is the case with prolonged ischemia times, inefficient organ 
preservation, or the use of extended-criteria donor organs. Severe inflammation leads to 
endothelial cell injury and impaired vascular homeostasis due to uncontrolled ROS production, 
and persistently elevated levels of proinflammatory cytokines, especially TNFα. The central 
mechanism underlying endothelial dysfunction is decreased nitric oxide (NO) bioavailability 
due to inhibition of endothelial nitric oxide synthase (eNOS) [46, 50, 51, 52]. Under normal 
physiological conditions, NO maintains vasodilation, suppresses platelet aggregation, prevents 
leukocyte adhesion, attenuates vascular smooth muscle cell proliferation, and inhibits the 
expression of proinflammatory cytokines (via downregulation of the NF-κB pathway) [46, 53, 
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54, 55]. Thus, the inhibition of eNOS due to oxidative stress and endothelial cell injury/death 
promotes vasoconstriction and leads to a pro-thrombotic and proinflammatory state [49, 50, 
51, 52, 53, 54, 55]. Furthermore, oxidative depletion of eNOS cofactor, tetrahydrobiopterin 
(BH4), in dysfunctional endothelial cells ‘uncouples’ eNOS resulting in the incomplete 
reduction of molecular oxygen and generation of more ROS [49, 56]. Finally, endothelial cell 
injury/death results in the loss of vascular integrity and increased vascular permeability 
facilitating leukocyte infiltration into graft tissue and the generation of an alloimmune response 
[21, 49, 50, 51]. 
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Figure 1 – Ischemia-Reperfusion Injury During Organ Transplantation 
In the transplant setting, ischemia occurs in two phases called the 'warm ischemia phase' and 
the 'cold ischemia phase.' Warm ischemia occurs when the blood supply of the donor organ is 
interrupted and lasts until the donor organ is flushed with a cold organ preservation solution. 
Cold ischemia occurs during organ preservation. Currently, the most common method of donor 
organ preservation is static cold (4°C) storage on ice. The donor organ undergoes another brief 
period of warm ischemia when it is removed from cold storage until blood flow to the graft is 
re-established [57, 58, 59]. 
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Figure 2 – Cellular Biology of Ischemia-Reperfusion Injury 
The most important biochemical abnormality in ischemic cells is the decreased intracellular 
generation of ATP. Loss of ATP leads to the failure of many energy-dependent cellular 
systems, including ATP-dependent ion pumps, which results in increased intracellular sodium 
and calcium. Anaerobic glycolysis leads to lactic acid accumulation, resulting in intracellular 
acidosis. Ultimately, the failure of the critical energy-dependent systems and altered cellular 
ionic homeostasis can lead to cell death. During reperfusion, there is increased generation of 
ROS due to impaired cellular/mitochondrial enzymes, dysfunctional ETC components and 
reduced cellular ROS-scavenging capacity. The ROS that are generated cause damage to lipids, 
proteins and DNA and along with increased intracellular calcium induce mPTP formation. 
mPTP formation leads to loss of PMF, as a result of which there is a further decline in ATP 
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production. mPTP formation also leads to the release of mitochondrial factors involved in PCD 
pathways [13, 18, 20]. 
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1.3 – Cardiac Allograft Dysfunction and Rejection 
The cumulative pathological changes induced by IRI and the subsequent inflammatory 
response have a detrimental impact on the outcome of cardiac transplantation. IRI contributes 
to alloimmune injury and influences short-term as well as long-term allograft survival and 
function (Figure 3) [8, 10, 11, 12]. 
1.3.1 – Primary Graft Dysfunction – Amongst the early complications, primary graft 
dysfunction (PGD) remains the leading cause of mortality in heart transplant recipients, with 
a 30-day mortality rate of ~30% [8, 60]. PGD presents as the failure of the graft to meet the 
circulatory requirements of the recipient due to ventricular dysfunction and develops within 24 
hours of transplantation. Although PGD is not associated with a discernible cause, numerous 
studies have postulated IRI as the predominant factor in its development [8, 59, 60, 61]. 
1.3.2 – Cardiac Allograft Rejection – The inflammatory insult associated with IRI promotes 
leukocyte recruitment (via endothelial adhesion molecules) and activation (via expression of 
proinflammatory cytokines/chemokines and release of cDAMPS). Leukocyte infiltration into 
the cardiac allograft perpetuates graft injury and initiates alloimmune responses, which 
culminates in allograft transplant rejection. Although the development of novel and effective 
immunosuppressive agents has significantly reduced the rejection rates, it continues to remain 
one of the major causes of death after cardiac transplantation [8, 10, 62]. Rejection can be 
classified as hyperacute, acute cellular (cell-mediated) or humoral (antibody-mediated) 
rejection [8, 10]. 
1.3.3 – Hyperacute Rejection – Hyperacute rejection occurs within minutes to hours following 
transplantation and manifests as severe graft failure with hemodynamic instability. It is 
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mediated by pre-formed antibodies directed against antigens in the cardiac allograft. The target 
antigens include human leukocyte antigens (HLA) and ABO blood antigens expressed on the 
allograft endothelial cells. The binding of the alloantibodies to these antigens activates the 
complement system, which results in endothelial disruption, thrombosis, hemorrhage, and 
irreversible rapid destruction of the graft by the recipient’s immune system [8, 63, 64]. 
Histologically, hyperacute rejection manifests as vasculitis and ischemic necrosis of the 
cardiac allograft due to occlusive thrombosis. The management of hyperacute rejection is 
complicated and involves pharmacological and mechanical circulatory support, along with 
intense immunosuppression and plasmapheresis to remove the circulating alloantibodies. 
Hyperacute rejection has a high mortality rate but is now uncommon due to comprehensive 
pre-transplant cross-match testing, including panel-reactive antibody (PRA) screening [8, 63, 
64, 65]. 
1.3.4 – Acute Cellular Rejection – Acute cellular rejection (ACR) is the most common type 
of rejection after cardiac transplantation, with over 60% of the patients experiencing one or 
more episodes [8, 62, 68, 69]. It generally occurs within the first six months post-
transplantation [8, 62, 69]. ACR involves coordination between the innate and the adaptive 
immune systems, with T cells playing a central role [8, 69, 70, 71]. Alloantigen recognition in 
ACR can occur via the direct or the indirect pathways. In the direct pathway of alloantigen 
recognition, recipient T cells recognize 'intact' non-self major histocompatibility complex 
(MHC) molecules on donor cells within the graft tissue. In the indirect pathway, 'processed' 
non-self MHC molecules are presented by recipient MHC molecules to recipient T cells [70, 
71, 72]. Of the professional antigen presenting cells (APCs), dendritic cells play the most 
important role in eliciting the alloimmune response by capturing and presenting antigens to the 
naive T cells in lymph nodes. The resulting primed T cells then migrate to, infiltrate, and attack 
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the graft tissue by multiple mechanisms, including lysis of graft cells, alloantibody production, 
complement activation, and recruitment of monocytes and macrophages [70, 72]. Various 
cytokines orchestrate the ACR response, the most important of which are TNFα, IL-1β, and 
CD40 [70, 73, 74, 75, 76]. Both CD4+ helper and CD8+ cytotoxic T cells are implicated in 
ACR [8, 69, 70, 71, 72]. Histologically, ACR is characterized by leukocyte infiltration with a 
predominance of T cells, edema, hemorrhage, myocyte damage/necrosis, and vasculitis [8, 69, 
71]. The incidence and management of ACR have significantly improved in the past few 
decades due to advancements in biopsy techniques, improved histopathological grading 
systems, and the development of potent immunosuppressive agents [8, 66, 67]. 
1.3.5 – Antibody-Mediated Rejection – Antibody-mediated rejection (AMR) typically occurs 
within the first few months following cardiac transplantation in 10-20% of the patients [77, 78, 
79]. Recipient antibodies directed against MHC Class I and Class II molecules on the surface 
of endothelial cells, activate the complement system, and initiate inflammatory pathways that 
cause injury to graft tissue [8, 77, 78, 79]. The recipient alloantibodies may be pre-formed and 
present prior to transplantation or may form following innate immune system activation after 
transplantation. Complement activation leads to endothelial cell and myocyte lysis via the 
formation of membrane attack complex (MAC) [66, 79, 80]. Since the primary focus of the 
recipient alloantibodies is the endothelium, the allograft microvasculature undergoes 
significant injury resulting in increased vascular permeability and intravascular thrombosis. 
The complement fragments C3a and C5a induce endothelial activation, and serve as potent 
chemokines for neutrophils and macrophages, which further augments the inflammatory injury 
through cytotoxic actions, ROS production and cytokine release [8, 77, 78, 79].  
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Histologically, AMR was initially described as a "biopsy-negative rejection" due to 
vasculitis, edema and hemorrhage in the absence of cellular infiltrate in the graft tissue; 
however, standardized clinical and pathological criteria for the diagnosis of AMR are now 
available [71, 77, 78, 79]. Myocardial capillaries, venules and arterioles display varying levels 
of injury depending on the severity of AMR, with vasculitis and leukocyte infiltration 
indicating an active AMR response. Interstitial edema, hemorrhage and intravascular thrombi 
may also be seen. AMR necessitates aggressive immunosuppression with more severe cases 
requiring plasmapheresis and hemodynamic support. Severe or persistent AMR may lead to 
cardiac allograft vasculopathy [8, 71, 77, 78, 79, 81, 82]. 
1.3.6 – Cardiac Allograft Vasculopathy – Cardiac allograft vasculopathy (CAV) represents a 
substantial barrier to the long-term survival of the cardiac allograft. It is the most significant 
determinant of patient survival after three years of cardiac transplantation and occurs in up to 
50% of the patients within ten years of the transplant procedure [8, 65, 83, 84, 85]. CAV is 
characterized by progressive diffuse concentric intimal hyperplasia and medial disease 
involving the epicardial and intramural arteries, arterioles, and capillaries with relative sparing 
of the venules and veins [71, 83, 85, 86]. The pathophysiologic factors involved in the 
development of CAV are both immunologic and non-immunologic. Immunologic factors 
include the degree of MHC mismatch between the donor and the recipient, and the severity of 
the acute rejection episodes, particularly those involving injury to the endothelium (such as 
AMR) [71, 83, 85]. Non-immunologic factors include age, sex, obesity, dyslipidemia, diabetes 
mellitus, hypertension, and graft IRI [66, 67, 83, 85]. Both immunologic and non-immunologic 
factors result in endothelial activation/dysfunction [8, 66, 67, 83, 85].  
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MHC molecules on the surface of graft endothelial cells activate recipient CD4+ helper 
and CD8+ cytotoxic T cells, which then orchestrate the graft injury and fibroproliferative repair 
processes by recruiting inflammatory cells and inducing cytokine secretion [83, 85, 86, 87]. 
The important cytokines include IL-2, TNFα, and IFNγ. IL-2 promotes T cell proliferation and 
differentiation while TNFα and IFNγ both increase the expression of MHC molecules and 
promote endothelial activation/dysfunction [83, 85, 87, 88, 89]. TNFα also has direct cytotoxic 
effects and IFNγ activates macrophages. The recruited macrophages contribute to graft injury 
and produce several growth factors such as platelet-derived growth factor (PDGF), insulin-like 
growth factor-1 (IGF-1) and transforming growth factors α and β (TGFα and β) [83, 88, 89]. 
These growth factors cause smooth muscle cell migration, proliferation, and extracellular 
matrix deposition in the intima, resulting in concentric thickening of the vasculature [8, 66, 67, 
83, 85, 86, 87, 88, 89, 90].  
Clinically, CAV is asymptomatic due to denervation of the transplanted graft and is 
difficult to detect. It is a progressive disease associated with adverse outcomes and may 
necessitate surgical intervention for revascularization and re-transplantation in the most severe 
cases. Furthermore, the current surveillance methods and diagnostic tools for the detection of 
CAV have significant limitations. Accordingly, prevention is an essential strategy [8, 83, 85, 
88, 91]. The use of statins and mammalian target of rapamycin (mTOR) inhibitors provide 
significant protection against CAV [8, 83, 91, 92]. Addressing the immunologic and non-
immunologic factors associated with the development of CAV is also important [8, 66, 83]. 
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Figure 3 – Clinical Consequences of Ischemia-Reperfusion Injury in Organ 
Transplantation 
The cumulative pathological changes induced by IRI causes cellular death and inflammation 
with life-threatening consequences in the immediate postoperative period, such as primary 
graft dysfunction/non-function. IRI contributes to acute and chronic alloimmune injury via 
cellular and humoral immune responses and has been shown to have deleterious long-term 
effects on graft survival and contributes to graft rejection. The use of potent 
immunosuppressive agents to induce graft tolerance is also associated with life-threatening 
adverse effects such as diabetes, infections and malignancy [8, 10, 12, 65, 66, 67, 77, 90]. 
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1.4 – The Endothelium in Cardiac Transplantation 
The endothelium is crucial in maintaining the vascular homeostasis by regulating 
thrombosis, thrombolysis, platelet adherence, vascular tone, and blood flow. It also plays an 
active part in immune surveillance by facilitating and limiting the recruitment of leukocytes 
and stimulating immune reactivity. In transplantation, it represents the first barrier between the 
graft tissue and the recipient's immune system. The role of the endothelium on the outcome of 
the transplantation procedure was often overlooked in the past [42, 93, 94]. This was 
particularly true for cardiac transplantation, where cardiomyocytes were considered more 
sensitive to IRI and the primary target of the alloimmune response. Several studies have now 
established that endothelial cells are not only more susceptible to IRI than cardiomyocytes but 
also perpetuate the graft IRI and play an active role in the subsequent alloimmune response 
[95, 96]. 
Endothelial cells undergo many of the pathological changes associated with IRI, 
including disruption of critical energy-dependent cellular systems, intracellular acidosis, 
electrolyte imbalances, cellular swelling, and damage to various biological molecules by ROS 
and degradative enzymes [49, 94, 95]. These changes can induce endothelial 
activation/dysfunction, injury, and death. Endothelial activation/dysfunction contributes to the 
inflammatory response associated with IRI by secreting proinflammatory cytokines (IL-1, IL-
6, IL-8, TNFα) and upregulating the expression of adhesion molecules (E-selectin, P-selectin, 
ICAM-1, VCAM-1) that facilitate leukocyte infiltration into the graft tissue [50, 51, 94]. Injury 
to the endothelial cells generates ROS and cDAMPS that perpetuate IRI and augment the 
inflammatory response [47, 48, 49, 50, 56]. Endothelial cells express many alloantigens and 
contribute to the development of alloimmune responses [8, 10, 65, 66, 67, 77, 90]. They also 
18 
 
express MHC molecules (Class I and II) and co-stimulatory molecules, including CD80 and 
CD86, that can activate naive T cells [97, 98, 99, 100]. Endothelial cells are the primary target 
in all types of graft rejection [8, 72, 77, 83, 94]. In the chronic setting, they play a crucial role 
in allograft vascular disease by stimulating the migration of smooth muscle cells to the intimal 
layer and deposition of fibrous matrix. Significant endothelial cell injury and death results in 
loss of vascular integrity and tone, increased vascular permeability, and intravascular 
thromboses, which disrupts blood flow, promotes inflammation and alloimmunity, and 
ultimately, contributes to graft injury and necrosis [8, 10, 65, 66, 67, 77, 90]. 
1.5 – Endothelial Cell Death  
At the cellular level, the cumulative pathological changes induced by IRI may lead to 
cell death, which may be unregulated or programmed (Figure 2) [101, 102, 105]. The 
detrimental effects of cell death on graft injury and alloimmunity have been extensively 
characterized. Inhibiting cell death in organ transplantation is important for two reasons. 
Firstly, uncontrolled cell death with insufficient replacement of cells adversely affects graft 
survival and function [102, 103, 104, 105]. Secondly, the release of cytoplasmic contents and 
cDAMPs from dying cells triggers and sustains alloimmune responses [13, 18, 20, 21]. Several 
different forms of programmed cell death (PCD) are now known, broadly classified as 
apoptosis and regulated necrosis types. The latter includes many further types, including 
necroptosis, pyroptosis, ferroptosis, and oxytosis, among others. [101, 102, 105]. As the role 
of these different forms of PCD in organ transplantation becomes increasingly evident, 
targeting these cell death pathways can potentially present novel therapeutic approaches to 
preserve graft function and survival. This is especially important considering the limited 
success of recipient immunosuppression in alleviating alloimmunity and prolonging graft 
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survival. Amongst the various regulated necrosis types, the detrimental role of necroptosis in 
inducing graft injury and alloimmunity is best characterized [102, 103, 104, 105].  
Endothelial cells are susceptible to the different forms of PCD induced by IRI (Figure 
4). Given the central role of the endothelium in developing and sustaining the alloimmune 
response, preventing endothelial cell death is particularly important. Several studies, including 
some from our group, have established the role of apoptosis and necroptosis in cardiac and 
other solid organ transplantation [8, 10, 25, 26, 27, 28, 32, 43, 44]. Understanding the mediators 
and the signal transduction pathways involved in the induction of endothelial cell necroptosis 
will help elucidate targets for mechanism-based inhibitors that can help preserve graft survival 
and function [102, 103, 104, 105].   
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Figure 4 – Programmed Cell Death Pathways Induced by Ischemia-Reperfusion Injury 
In the context of IRI, the major PCD pathways studied include apoptosis, necroptosis and 
parthanatos. The mitochondria play a critical role in inducing all of the PCD pathways 
associated with IRI. Although the downstream mechanisms involved in necroptosis are not 
established, most studies strongly support a role for the mitochondria in necroptosis and 
suggest the involvement of the CypD-mediated mPTP formation [13, 102, 105, 106, 107]. 
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1.6 – Necroptosis 
1.6.1 – Shared Upstream Pathway of Apoptosis and Necroptosis – The upstream signaling 
pathways of apoptosis (extrinsic) and necroptosis are shared (Figure 5). In organ 
transplantation, apoptosis and necroptosis can both be initiated due to direct and severe injury 
to the cell or due to proinflammatory cytokines and factors. The ligation of TNFα with TNF-
receptor 1 (TNF-R1) mediates the best characterized pathway of necroptosis. Necroptosis can 
also be initiated by TLR3, TLR4, Fas ligand, and TNF-related apoptosis-inducing ligand 
(TRAIL) [102, 103, 104, 105, 106]. IRI involves the expression of several of these factors as 
well as necroptosis-inducing injury to the cells such as ROS-mediated damage and calcium 
overload [13, 18, 20]. 
The binding of TNFα to TNF-R1 recruits TNF receptor-associated death domain 
protein (TRADD), TNF-receptor associated factors 2 and 5 (TRAF2/5), cellular inhibitors of 
apoptosis 1 and 2 (cIAP1/2), linear ubiquitin chain assembly complex (LUBAC), and receptor-
interacting serine/threonine protein kinase 1 (RIPK1). This complex of proteins is called 
‘Complex I.’ cIAP1/2, and LUBAC possess E3 ubiquitin ligase activity and polyubiquitinate 
RIPK1. This results in signaling through the pro-survival NF-κB pathway and counters the 
cytotoxic effects of TNFα [102, 103, 104, 105, 106].  
In the presence of persistent or severe injury, RIPK1 is deubiquitinated by the enzymes 
A20 and cylindromatosis (CYLD). CYLD is a deubiquitinase that counters the ubiquitin ligase 
activities of cIAP1/2 and LUBAC and removes the ubiquitin chains from RIPK1. 
Deubiquitinated RIPK1 dissociates from Complex I and interacts with FAS-associated Death 
Domain (FADD), procaspase-8 and cellular FLICE-like inhibitory protein (c-FLIP) to form 
the ‘Death Inducing Signaling Complex’ (DISC) or ‘Complex IIa.’ c-FLIP has three different 
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splice variants, c-FLIPL, c-FLIPS and c-FLIPR, which regulate the activity of caspase-8 
differently. c-FLIPS and c-FLIPR inhibit apoptosis by preventing caspase-8 processing and 
activation. c-FLIPL is an enzymatically inert homolog of caspase-8 and its activity is dependent 
on its expression levels, which in turn is dependent on the extent of cellular injury and the level 
of NF-κB activation [102, 105, 108].  
When expressed at low levels, c-FLIPL forms a heterodimer with procaspase-8 and 
activates it. Activated caspase-8 is considered the ‘initiator’ caspase. It forms homodimers that 
activate the procaspases-3, -6 and -7 to their ‘effector’ active forms, which mediate cell death 
via apoptosis. The c-FLIPL/caspase-8 heterodimer prevents necroptosis by cleaving the crucial 
necroptotic mediators RIPK1 and RIPK3. The inhibitory effect of c-FLIPL/caspase-8 
heterodimer on necroptosis explains why caspase-8 deficient mice are embryonically lethal 
and why RIPK3 deficiency in these mice rescues them from lethality [102, 107, 108]. This also 
indicates that, in addition to promoting apoptosis, an important function of caspase-8 is to 
prevent necroptosis. When expressed at high levels, c-FLIPL partially processes procaspase-8, 
the cleavage activity of which is limited to DISC. This partially processed caspase-8 cleaves 
the DISC associated proteins, including RIPK1 and itself, and prevents both apoptosis and 
necroptosis [102, 103, 104, 107, 108].  
It is important to note that the ubiquitination status of RIPK1 determines cellular fate. 
RIPK1 ubiquitination promotes cellular survival by restricting the interactions of the pro-
apoptotic caspase-8 and the pro-necroptotic RIPK3 with RIPK1. Deubiquitination of RIPK1 
promotes cell death by permitting the interaction of caspase-8 and RIPK3 with RIPK1 and 
activating the downstream death pathways [102, 105, 106, 107, 108].   
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1.6.2 – The ‘Necrosome’ – If caspase-8 activity is disrupted (in case of mutation, inhibitory 
viral proteins or ischemia), RIPK1 detaches from DISC and interacts with RIPK3 via the RIP 
homotypic interaction motif (RHIM) domains. RIPK1 and RIPK3 then auto- and trans-
phosphorylate each other to form the 'necrosome' or 'Complex IIb.' The necrosome-associated, 
phosphorylated RIPK3 then phosphorylates mixed lineage kinase domain-like protein 
(MLKL), which initiates the downstream signaling in necroptosis. When overexpressed, 
RIPK3 can also phosphorylate MLKL independent of RIPK1 [102, 105, 106, 109, 110]. 
1.6.3 – Downstream Pathway of Necroptosis – It is now established that necrosome formation 
and phosphorylation of MLKL are essential for necroptosis; however, the precise pathway 
downstream of necrosome formation is unclear. Several studies have been conducted to 
elucidate the downstream pathway involved in necroptosis with contradictory results. 
However, most studies have suggested that the mitochondria, in one form or another, play a 
pivotal role in necroptosis [102, 105, 106]. 
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Figure 5 – Necroptosis Mediators and Signaling Pathway 
The best-characterized pathway of necroptosis involves the ligation of TNFα with TNF-R1, 
which recruits TRADD, TRAF2/5, cIAP1/2, LUBAC and RIPK1 to form Complex I. cIAP1/2 
and LUBAC then polyubiquitinate RIPK1 which results in signaling through the pro-survival 
NF-κB pathway. Persistent/severe injury results in RIPK1 deubiquitination by the enzymes 
A20 and CYLD. Deubiquitinated RIPK1 interacts with FADD, procaspase-8 and c-FLIPL to 
form Complex IIa. c-FLIPL differentially regulates the activation/inhibition of caspase-8 
depending on its expression levels. Activated caspase-8 induces apoptosis via activation of 
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caspases-3, -6 and -7; however, if caspase-8 activity is disrupted, RIPK1 interacts with RIPK3 
to form Complex IIb. RIPK1 and RIPK3 then auto- and trans-phosphorylate each other and 
also phosphorylate MLKL, which initiates the downstream signaling in necroptosis [102, 105, 
106, 109, 110]. 
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1.7 – Mitochondria in Cell Death 
Mitochondria are highly dynamic organelles that have vital roles in cellular 
bioenergetics, metabolism, biosynthesis, and regulation of diverse signals that determine the 
fate of the cell. Cellular injury leads to mitochondrial dysfunction that disrupts the 
mitochondrial functions integral to the survival of the cell and activates signals that promote 
cell death. Although mitochondria are involved in several forms of PCD, their role in apoptosis 
and necroptosis is most relevant to IRI (Figures 5 and 7) [104, 106, 111, 112, 113]. 
1.7.1 – Role of Mitochondria in Apoptosis – Apoptosis can be initiated through two different 
pathways - extrinsic (via death receptor stimulation) and intrinsic. Although mitochondria are 
involved in both pathways, they have a more critical role in the intrinsic pathway of apoptosis 
(Figure 5) [111, 112, 113]. Pathological changes associated with cell injury such as ROS-
mediated oxidative damage, intracellular calcium overload, and DNA damage (all of which 
may result from IRI) can initiate the intrinsic pathway of apoptosis by permeabilization of the 
outer mitochondrial membrane (OMM). Mitochondrial outer membrane permeabilization 
(MOMP) is normally tightly regulated by the B cell lymphoma 2 (Bcl-2) family of pro- and 
anti-apoptotic members. Following an apoptotic stimulus, the pro-apoptotic Bcl-2 associated 
X protein (BAX) and Bcl-2 homologous antagonist killer (BAK) undergo conformational 
changes and form homo-oligomers that form pores in the OMM. Permeabilization of the OMM 
releases pro-apoptotic proteins such as Cytochrome C (Cyt C) and second mitochondria-
derived activator of caspases (SMAC)/direct IAP binding protein with low pI (DIABLO) [111, 
112, 113, 114]. Cyt C is an essential ETC component that interacts with apoptotic protease 
activating factor 1 (Apaf-1), procaspase-9 and dATP to form the apoptosome. The apoptosome 
activates procaspase-9 to the 'initiator' caspase-9 that cleaves procaspases-3, -6 and -7 to their 
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active forms. SMAC/DIABLO promotes apoptosis by neutralizing the inhibitory effect of IAPs 
on caspases [102, 111, 112, 113, 114]. 
The extrinsic pathway of apoptosis, triggered by death receptor stimulation, is linked 
to the intrinsic pathway of apoptosis by the pro-apoptotic Bcl-2 protein, BH3 interacting-
domain death agonist (BID). Caspase-8 cleaves BID into its truncated form, tBID, which 
promotes the OMM permeabilization by BAX and BAK and release of Cyt C and 
SMAC/DIABLO [111, 112, 113, 114].  
1.7.2 – Role of Mitochondria in Necroptosis – As explained earlier, most studies suggest a 
role for mitochondria in necroptosis. However, even for the studies indicating a mitochondrial 
role, the precise signaling pathway is a point of contention (Figures 5 and 7) [106]. The earliest 
studies done to investigate the mitochondrial role in necroptosis suggested that the involvement 
of ROS generation is secondary to mitochondrial damage and ETC disruption [115, 116, 117, 
118, 119]. These studies have shown the formation of necrosome and its translocation to the 
mitochondria along with pMLKL following TNFα signaling [106, 115, 116, 117, 120, 121, 
122, 123]. Furthermore, the use of the antioxidant butylated hydroxyanisole prevented ROS 
generation and TNFα-induced necroptosis [115, 116]. In other studies, the ROS generated were 
determined to be mitochondrially derived. Inhibiting cytoplasmic ROS generation by the 
enzyme NADPH oxidase did not inhibit TNFα-induced necroptosis; however, suppression of 
the ETC complex I and the use of the mitochondria-specific ROS scavenging enzyme, 
mitochondrial superoxide dismutase (MnSOD), did [115, 116, 122]. There is also evidence 
suggesting the involvement of the mitochondrial enzyme glutamate dehydrogenase 1 
(GLUD1) in TNFα-induced ROS production and necroptosis [121].  
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The involvement of the mitochondrial factors serine/threonine-protein phosphatase 5 
(PGAM5) and Dynamin-related protein 1 (Drp1) in necroptosis have also been studied [123, 
124]. According to these studies, following necroptosis induction, the necrosome and pMLKL 
translocate to the mitochondria, where they activate PGAM5. PGAM5 then recruits and 
activates Drp1 by dephosphorylation of serine 637 of Drp1. Activated Drp1 induces 
mitochondrial fragmentation, resulting in necroptosis. In support of these findings, Drp1 
inhibition (with Mdivi-1) and deficiency have been shown to reduce TNFα-induced 
necroptosis. Furthermore, coimmunoprecipitation assays have indicated a direct interaction 
between necrosome and PGAM5 following TNFα signaling [123, 124]. 
Among the proposed mitochondrial mediators of necroptosis, evidence for the role of 
mPTP is the strongest [104, 106]. As explained earlier, IRI induces the formation of mPTP, 
which leads to cellular demise via ΔΨm dissipation, ATP depletion, ROS production, and 
mitochondrial swelling and rupture, releasing various cell death mediators [20]. Genetic 
experiments involving cells and mice deficient for cyclophilin D (CypD), a critical regulator 
of mPTP opening, have shown resistance to cell death induced by necroptotic mediators. 
Furthermore, these experiments have also shown that the protection conferred by CypD 
inhibition or ablation is not additive to that conferred by blocking the upstream signaling 
pathway in necroptosis [125, 126, 127]. 
It is important to note that some studies have indicated that necroptosis can occur 
independently of mitochondria. In a study investigating the role of mitochondria in necroptosis, 
widespread mitochondrial depletion via mitophagy did not prevent TNFα-induced necroptosis 
[128]. The role of mitochondrial ROS, PGAM-Drp1 axis and mPTP formation in necroptosis 
is also disputed and not fully established. Several studies have shown that treatment with a 
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variety of antioxidants did not attenuate cell death following ROS production in response to 
TNFα signaling. Similarly, necroptosis was observed in cells despite PGAM5 and Drp1 
knockdown [128, 129, 130, 131]. Although evidence for the role of mPTP in necroptosis is 
strongest, findings from one study have questioned its role. This study reveals that 
simultaneous RIPK3 and CypD ablation provides greater protection against necroptosis than 
separate RIPK3 and CypD depletions in the context of renal IRI [132]. The most compelling 
studies disputing the role of mitochondria in necroptosis indicate that necrosome formation is 
followed by phosphorylation and oligomerization of MLKL. Oligomerized pMLKL 
complexes then translocate to the plasma membrane, where they compromise its integrity by 
forming holes [133, 134, 135, 136]. 
1.8 – Mitochondrial Permeability Transition Pore 
The outer and inner membranes of the mitochondria are different from each other in 
several aspects. OMM is relatively permeable due to the presence of the voltage-dependent 
anion channels (VDAC), which form general diffusion pores for ions and hydrophilic 
molecules between the mitochondria and cytosol. The inner mitochondrial membrane (IMM), 
on the other hand, is highly impermeable and effectively separates the mitochondrial matrix 
from the cytosol. Movement of ions and metabolites across IMM involves specialized 
membrane transporters [20, 137, 138]. The ETC complexes are embedded within IMM and are 
responsible for establishing the ΔΨm by creating a proton gradient across IMM. This proton 
gradient is used by the 'F1/F0 ATP synthase' to generate ATP. Increased permeability of IMM 
disrupts the proton gradient and the ΔΨm, resulting in decreased ATP synthesis. It also enables 
the loss of ETC components, which results in the incomplete reduction of oxygen and ROS 
production [140, 141]. The loss of mitochondrial antioxidants compromises the ROS 
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neutralizing ability of the mitochondria and further augments oxidative damage. The 'pore' 
responsible for the increased permeability of the IMM is the entity termed 'mPTP' (Figure 6) 
[20, 137, 138, 139, 140, 141].  mPTP formation also results in the influx of metabolites (<1.5 
kDa) and water into the mitochondrial matrix leading to osmotic swelling. Swelling of the 
mitochondrial matrix may not compromise the integrity of IMM because of cristae unfolding, 
but it exerts pressure on OMM and ruptures it. This releases cell death mediators, such as the 
pro-apoptotic ETC component Cyt C, resulting in cellular demise [20, 137, 138, 139].  
1.8.1 – Structural Components of mPTP – While the pathological consequences of mPTP 
formation are well established, its exact structural components are still disputed. According to 
the classical model, mPTP spans the mitochondrial intermembrane space and comprises of 
VDAC in OMM and adenine nucleotide translocator (ANT) in IMM, besides the regulatory 
component, CypD, in the mitochondrial matrix. Although genetic tests do not fully support the 
roles of VDAC and ANT, the role of CypD in regulating mPTP formation is well established. 
[106, 137, 138]. CypD regulation of mPTP formation occurs even in the absence of VDAC 
and ANT [20, 106, 137, 138].  
Recent studies have suggested that the OMM component of mPTP may be formed by 
the pro-apoptotic Bcl-2 proteins BAX and BAK that form MOMP in their active oligomerized 
state [138, 142, 143]. According to this more current model, the IMM component is formed by 
the c-subunit of F1/F0 ATP synthase. CypD binds with the oligomycin sensitivity-conferring 
protein (OSCP) of F1/F0 ATP synthase and triggers mPTP formation through its dimerization. 
This model also suggests that the two structural components of mPTP do not form in apposition 
to form a contiguous pore [142, 143]. The regulation of mPTP occurs at F1/F0 ATP synthase 
in IMM while MOMP is relatively non-selective. Some studies have also suggested that BAX 
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and BAK generate a low level of OMM permeability even in their non-oligomerized (inactive) 
states, although evidence for this is inconclusive (Figure 6) [137, 138, 139, 142, 143].  
1.8.2 – Formation of mPTP in IRI – Under physiological conditions, brief and abrupt mPTP 
formation (mPTP flickering) is considered a mitochondrial calcium efflux mechanism and 
maintains calcium homeostasis [137, 144]. IRI results in ROS generation and increased 
intracellular calcium, the two most potent triggers of prolonged and pathological mPTP 
formation [13, 106, 139, 140, 141]. As explained earlier, ischemia results in insufficient ATP 
levels, increased intracellular sodium and calcium and decreased intracellular pH. Although 
ischemia is associated with increased intracellular calcium, mPTP formation is not observed. 
This may be due to the hydrogen ions competing with the calcium ions at the trigger site. 
Reperfusion is associated with the additional generation of ROS, further calcium overload and 
restoration of the intracellular pH. The removal of the accumulated hydrogen ions enables the 
increased intracellular calcium to trigger the formation of mPTP. ROS-mediated oxidative 
damage promotes mPTP formation by sensitizing mPTP to increased calcium levels and by 
increasing CypD interaction with the IMM component of mPTP (Figure 5) [13, 18, 20]. 
1.8.3 – Role of mPTP in Necroptosis – As explained earlier, evidence supporting the role of 
mitochondria in necroptosis is most indicative of mPTP formation (Figure 5). Recent studies 
have suggested that the precise mechanism of necroptosis may involve the release of pro-
necroptotic mediators following mPTP formation [104, 145, 146]. The putative mitochondrial 
pro-necroptotic mediators currently being investigated are apoptosis-inducing factor (AIF) and 
endonuclease G (Endo G). AIF and Endo G are mitochondrial proteins that translocate to the 
nucleus following their release into the cytosol and mediate DNA fragmentation, a 
characteristic finding observed in necroptosis [145, 146]. According to a recent study, CypD 
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inhibition prevents AIF and Endo G translocation to the nucleus [145]. Furthermore, as with 
RIPK1 and RIPK3 inhibition, CypD and AIF/Endo G silencing are protective against IRI, 
suggesting their role in necroptosis [147, 148]. mPTP formation in IRI may also lead to ROS 
generation, another potential mediator of necroptosis and ATP depletion that ultimately leads 
to unregulated necrosis (Figure 7) [13, 18, 20, 106].  
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Figure 6 – Mitochondrial Permeability Transition Pore Components and Structure 
The classical model of mPTP involves VDAC in the OMM, ANT in the IMM and the 
regulatory component CypD in the mitochondrial matrix. Although genetic tests do not fully 
support the roles of VDAC and ANT, CypD regulation of mPTP formation occurs even in the 
absence of VDAC and ANT. According to the current model of mPTP, the OMM component 
of mPTP may be formed by the pro-apoptotic Bcl-2 proteins BAX and BAK that form MOMP 
in their active oligomerized state while the IMM component is formed by F1/F0 ATP synthase. 
CypD binds with OSCP of F1/F0 ATP synthase and triggers mPTP formation through its 
dimerization. This model also suggests that the two structural components of mPTP do not 
form in apposition to form a contiguous pore. The regulation of mPTP occurs at F1/F0 ATP 
synthase in IMM, while MOMP is relatively non-selective [137, 138, 142, 143]. 
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Figure 7 – Role of Mitochondria in Programmed Cell Death Pathways 
Mitochondria play a critical role in unregulated necrosis and PCD. MOMP formation 
contributes to apoptosis via the release of Cyt C, cIAP1/2 and SMAC/DIABLO. Following 
cellular injury (especially IRI), mPTP formation may contribute to ROS production, which 
have a role in inducing necroptosis in several cell types. mPTP formation also facilitates the 
release of AIF/Endo G, which then translocate to the nucleus and mediate DNA fragmentation, 
a characteristic finding observed in necroptosis and parthanatos. Finally, persistent mPTP 
formation results in loss of PMF and ΔΨm, resulting in failure of critical energy-dependent 
cellular systems and cell death via unregulated necrosis [13, 18, 20, 104, 106, 111, 145, 146, 
147, 148, 149]. 
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1.9 – Apoptosis-Inducing Factor 
AIF is a mitochondrial flavoprotein that, under physiological conditions, has essential 
pro-survival functions. AIF has oxidoreductase activity and is crucial for the biogenesis and 
stabilization of key ETC components, Complex I and Complex III [147, 148]. Harlequin (Hq) 
mice, which have a hypomorphic AIF mutation (80% reduction) due to proviral insertion at 
the X-linked Aifm1 (AIF gene) locus, display phenotypic changes characteristic of 
mitochondrial diseases and disruption in energy metabolism. These mice develop severe 
neuromuscular mitochondriopathies and exhibit progressive hair loss, neurodegeneration, 
ataxia and blindness due to retinal degeneration [147, 148, 149]. Cardiac and skeletal muscle-
specific AIF knockout results in cardiomyopathy and skeletal atrophy [146, 147, 148, 151]. 
Consistent with these findings, in vitro experiments indicate that cells lacking AIF have high 
lactic acid production due to ETC disruption and anaerobic glycolysis [145, 146, 147, 148, 
149].  
Although mitochondrion-localized AIF has pro-survival functions, extra-mitochondrial 
AIF is involved in PCD (Figure 8). Following its release into the cytoplasm, AIF translocates 
to the nucleus and triggers caspase-independent cell death by inducing DNA damage. AIF-
mediated DNA degradation has been shown to occur in response to several types of pathologic 
insults, including IRI. Mitochondria purified following IRI show a decrease in their AIF 
content and presence of AIF in the nucleus [147, 148]. There is limited evidence suggesting 
that inhibition of the upstream necroptotic pathway and blocking mPTP formation restricts 
AIF-mediated DNA fragmentation [145, 148]. Furthermore, mitochondrial calcium overload, 
a potent trigger for mPTP formation, also induces AIF release [145, 147, 148].  
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Figure 8 – Role of Apoptosis-Inducing Factor in Programmed Cell Death 
Mitochondrion-localized AIF has essential pro-survival functions in cellular bioenergetics; 
however, extra-mitochondrial AIF is involved in PCD. Following its release into the cytoplasm 
by a death-inducing signaling event, AIF is cleaved to its truncated form and translocates to 
the nucleus where it mediates large-scale DNA fragmentation via activation of an unidentified 
endonuclease. Recent studies have suggested that mPTP formation may facilitate the release 
of AIF from the mitochondria. AIF translocation to the nucleus is inhibited by HSP-70 and 
facilitated by CypA [145, 146, 147, 148]. 
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1.10 – Study Rationale 
A growing body of evidence indicates that necroptosis is a highly inflammatory form 
of PCD that contributes to IRI-mediated allograft injury and promotes recipient alloimmune 
responses [102, 105]. As such, it represents a relevant therapeutic target in the clinical 
management involving organ transplantation. Previous studies from our lab suggest that 
necroptosis contributes to kidney IRI and promotes cardiac and renal allograft rejection [103, 
104]. We have also shown that inhibition of RIPK3 and CypD prevents necroptosis in murine 
microvascular endothelial cells, thereby establishing the significance of these mediators in the 
necroptotic pathway. In our previous studies, inhibition of RIPK3 and CypD attenuated 
allograft rejection and promoted graft survival [103, 104]. Although the upstream signaling 
molecules and pathways involved in necroptosis are well-established, the role of mitochondria 
and the downstream mediators involved are mostly unknown [102, 106]. The main objective 
of this study was to investigate the precise role of CypD-mediated mPTP formation in 
promoting mitochondrial damage and release of mediators involved in DNA fragmentation 
associated with hypoxia/reoxygenation-induced necroptosis. We also translated findings from 
our previous studies supporting the role of CypD inhibition in promoting graft survival to a 
clinically relevant model involving prolonged cold ischemic organ storage followed by 
heterotopic transplantation. 
1.11 – Hypothesis  
We hypothesize that ischemia-reperfusion injury induces mitochondrial damage, 
release of mitochondrial factors, and activation of the downstream mechanisms of nuclear 
fragmentation, thus promoting allograft injury and transplant rejection. 
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1.12 – Study Aims 
1. To determine the role of CypD in endothelial cell death following in vitro cold 
hypoxia-reoxygenation injury.  
2. To determine the effectiveness of CypD inhibition in attenuating IRI-
aggravated transplant rejection and prolonging graft survival. 
3. To investigate the mitochondrial mechanism(s) involved in mediating DNA 
fragmentation in hypoxia/reoxygenation-induced endothelial cell necroptosis.  
4. To determine the effectiveness of inhibiting the mitochondrial mechanism(s) involved 
in mediating DNA fragmentation in attenuating IRI-mediated transplant rejection and 
prolonging graft survival. 
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Chapter 2 
MATERIALS AND METHODS 
2.1 – Mice 
Wild-type (WT) C57BL/6 (B6), BALB/c and B6 CypD-/- mice were purchased from 
the Jackson Laboratory (Bar Harbor, ME, USA). The mice were maintained in the Animal 
Care and Veterinary Services facility at Western University. All animal use protocols and 
experimental procedures were approved by the institutional Animal Care Committee.   
2.2 – Cardiac Transplantation and Post-Operative Monitoring 
Donor hearts from WT and CypD-/- mice were heterotopically transplanted into the 
abdominal region of BALB/c mice. The mice were anesthetized with a mixture of 
ketamine/xylazine before the transplantation procedures. Donor hearts were removed after 
clamping the aortae, vena cavae and pulmonary arteries and veins. They were then flushed 
with cold normal saline and stored in Lactated Ringer’s buffer (Baxter International Inc., 
Deerfield, IL, USA) at 4°C for 4 hours before heterotopic transplantation into the abdominal 
cavity in recipient mice. Aortae from the donor hearts were sutured to the recipient mice 
abdominal aortae and the donor heart pulmonary arteries were sutured to the recipient mice 
inferior vena cavae. The vena cavae and pulmonary veins in the donor hearts were sutured 
shut. The hearts were observed for spontaneous contractions following transplantation before 
the recipient mice were sutured close. Cardiac transplantation experiments were performed by 
experienced microsurgeons at the Matthew Mailing Centre for Translational Transplantation 
Studies at the London Health Sciences Centre according to institutionally approved protocols. 
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Following the transplantation procedure, the immunosuppressive sirolimus (rapamycin; LCL 
Laboratories, Woburn, MA, USA) at 1 mg/kg was given from the operative day to 
postoperative day 9. Graft survival was monitored daily by abdominal palpation for pulse 
detection. Cessation of or significant drop in pulsation was considered as graft rejection and 
confirmed by histopathological analysis.  
2.3 – Histology and Immunohistochemistry  
Cardiac allografts in the recipient mice were collected on the day of rejection or at 21 
days post-transplantation for pathological analysis. The recipient mice were anesthetized with 
a mixture of ketamine/xylazine before the abdominal cavities were opened and the allografts 
removed. The isolated cardiac allografts were then flushed with normal saline, fixed with 10% 
neutral buffered formalin and embedded in paraffin for sectioning. The tissue sections were 
then stained with Hematoxylin & Eosin (H&E) and Verhoeff–Van Gieson elastic stain to 
evaluate damage to microvasculature, neointima formation and fibrosis. The tissue sections 
were also stained with anti-CD3 and anti-CD68 antibodies (eBioscience, San Diego, CA, USA) 
to evaluate and quantify T cell and macrophage infiltration, respectively. Tissue sectioning and 
staining was done by a laboratory technician according to the manufacturers’ protocols. Graft 
injury was evaluated based on the change in endothelium and leukocyte infiltration compared 
to naïve tissue by a pathologist in a blinded manner. The following changes were evaluated 
and quantified: damage to microvasculature, neointima formation, fibrosis, and leukocyte 
infiltration. The criteria used scored the injury on a scale of 0-4 as follows – 0: no change, 1: 
0-24% change, 2: 25-49% change, 3: 50-74% change, and 4: >75% change.  
2.4 – Endothelial Cell Culture 
41 
 
Endothelial cells were isolated as per the established protocol described previously 
[103]. Endothelial cells were isolated from the ventricles of 3-4 weeks old WT and CypD-/- 
mice. The major vessels (aortae, pulmonary veins and vena cavae) and atrial tissue were cut 
out and discarded. The ventricles were washed thoroughly with Dulbecco’s Phosphate 
Buffered Saline (PBS; Thermo Fisher Scientific, Mississauga, ON, Canada) and minced before 
incubation in D‐Hank's digestion buffer containing Collagenase II (1 mg/mL) and Dispase II 
(2 mg/mL) (Thermo Fisher Scientific, Mississauga, ON, Canada) at 37°C for 40 mins. The cell 
suspension was filtered using a 100 µm nylon mesh filter and then incubated with anti‐CD31 
coated Dynal magnet beads (Invitrogen, Burlington, ON, Canada) for 30 mins. The isolated 
CD31-positive cells were then washed and grown in Endothelial Cell Growth Basal Medium-
2 (EBM-2; Lonza, Mississauga, ON, Canada) containing 5% fetal bovine serum (FBS), 0.04% 
hydrocortisone, 0.4% human fibroblast growth factor (hFGF), 0.1% vascular endothelial cell 
growth factor (VEGF), 0.1% R3‐insulin-like growth factor-1 (R3-IFG‐1), 0.1% ascorbic acid, 
0.1% human epidermal growth factor (hEGF) and 0.1% gentamicin-sulfate amphotericin 1000 
(GA‐1000). The phenotype of isolated endothelial cells was confirmed by flow cytometry 
analysis of CD31, CD102 and CD105 (eBioscience, San Diego, CA, USA). The positively 
staining cells were then immortalized by origin-defective SV40-plasmid transfection.  
Normal cell culture medium used to grow endothelial cells was prepared by 
supplementing 1 g/L glucose Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher 
Scientific, Mississauga, ON, Canada) with 10% FBS and 1% penicillin/streptomycin. Cells 
were passaged a maximum of ten times with 0.25% trypsin (Life Technologies, Burlington, 
ON, Canada) before being discarded.  
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CypD-/- endothelial cells did not display any phenotypic changes as compared to WT 
endothelial cells. The growth and baseline turnover of the CypD-/- endothelial cells were 
comparable to the WT endothelial cells.    
2.5 – RNA Interference Silencing  
WT endothelial cells were seeded on 6-well plates and grown to 60-80% confluency in 
normal cell culture medium. The cells were washed with PBS before transfection with ON-
TARGETplus Mouse Aifm1 siRNA (Dharmacon, Lafayette, CO, USA) using EndoFectin™ 
Max transfection reagent (Genecopoeia, Rockville, MD, USA) in Opti-MEM® media 
(Invitrogen, Carlsbad, CA, USA). ON-TARGETplus Mouse Aifm1 siRNA was used at various 
concentrations from 100 nM – 800 nM. siRNA-induced silencing of Aifm1 expression was 
confirmed by quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and 
Western Blot, respectively at 24-, 48-, 72- and 96-hours post-transfection. Based on RT-qPCR 
and Western Blot results, the manufacturer-recommended dose of 200 nM was used for this 
study. The AIF-silenced cells were harvested at 48-hours post-transfection by 0.25% trypsin 
for cell death assays.  
2.6 – RT-qPCR  
siRNA-induced silencing of Aifm1 expression was confirmed by RT-qPCR at 24-, 48-
, 72- and 96-hours post-transfection. Total RNA from scrambled siRNA-transfected cells and 
Aifm1 siRNA-transfected cells was extracted using TRIzol Reagent (Invitrogen, Carlsbad, CA, 
USA). The concentration and purity of the isolated RNA was measured using the NanoDrop™ 
2000 Spectrophotometer (Thermo Fisher Scientific, Mississauga, ON, Canada). cDNA was 
generated from RNA using SuperScript™ II Reverse Transcriptase (Thermo Fisher Scientific, 
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Mississauga, ON, Canada). RT-qPCR was performed using Brilliant II SYBR® Green QPCR 
Master Mix (ABM, Vancouver, BC, Canada) and CFX Connect™ Real-Time PCR Detection 
System (Bio-Rad, Hercules, CA, USA). The Aifm1 primers used are as follows: Aifm1 forward 
primer (5’ – 3’) GTA GAT CAG GTT GGC CAG AAA CTC and Aifm1 reverse primer (5’ – 
3’) GGA TTA AAG GCA TGT GCC AAC ACG. β-actin was used as endogenous control for 
gene expression analysis. β-actin primers used are as follows: β-actin forward primer (5’ – 3’) 
CCA GCC TTC CTT CCT GGG TA and β-actin reverse primer (5’ – 3’) CTA GAA CAT 
TTG CGG TGC A. The ΔCt values for Aifm1 and β-actin were used to calculate the 2-ΔΔCt to 
get the expression fold change.  
2.7 – Western Blots 
 siRNA-induced silencing of AIF protein expression was confirmed by Western Blot 
analysis at 24-, 48-, 72- and 96-hours post-transfection. Total protein from scrambled siRNA-
transfected cells and Aifm1 siRNA-transfected cells was extracted using RIPA Lysis and 
Extraction Buffer (Thermo Fisher Scientific, Mississauga, ON, Canada) with Thermo 
Scientific™ Pierce Protease Inhibitor Cocktail Tablets (Thermo Fisher Scientific, Mississauga, 
ON, Canada). The concentration and purity of the isolated protein was measured by Bradford 
Dye Protein Assay using GENESYS™ 10S UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Mississauga, ON, Canada). The isolated protein samples were denatured by boiling 
in a loading buffer (4% SDS, 5% 2-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, 
0.125 M Tris-HCl; pH adjusted to 6.8) at 95°C for 5 minutes. The protein samples were then 
equally loaded (30-40 μg) in the wells of 10% SDS-PAGE gel and the gel was run at 100 V 
for ~1.5 hours in the electrophoresis apparatus with 1X running buffer (25 mM Tris base, 192 
mM glycine, 0.1% SDS; pH adjusted to 8.3). The separated protein samples were transferred 
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onto polyvinylidene fluoride (PVDF; activated with methanol) membrane in a transfer 
apparatus filled with ice-cold 1X transfer buffer (25 mM Tris base, 192 mM glycine, 20% 
methanol; pH adjusted to 8.3). The transfer cassette was prepared with the PVDF membrane, 
filter paper and fiber pads and the transfer apparatus was placed in ice and run at 70 V for ~1.5 
hours. Once the protein samples were transferred onto the PVDF membrane, the membrane 
was blocked with 5% bovine serum albumin (BSA) in TBS-T (20 mM Tris base, 150 mM 
NaCl, 0.1% Tween-20) on a standard analogue shaker (VWR, Mississauga, ON, Canada) at 
room temperature for 1 hour. After blocking, the PVDF membrane was incubated with primary 
rabbit anti-mouse AIF antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:1000 
dilution in 2.5% BSA in TBS-T overnight at 4°C. The PVDF membrane was then washed with 
TBS-T 3X for 15 minutes each time before incubation with HRP-conjugated secondary goat 
anti-rabbit antibody (Cell Signaling Technology, Danvers, MA, USA) at 1:1000 dilution in 
2.5% BSA in TBS-T at 4°C for 1 hour. The PVDF membrane was then washed with TBS-T 
3X for 10 minutes each time before it was developed for protein visualization using the HRP 
chemiluminescent substrate (EMD Millipore, Burlington, MA, USA) and imaged in the 
FluorChem M Imaging System. The housekeeping proteins, β-actin and/or GAPDH, were used 
as loading controls. Murine anti-mouse β-actin antibody (MilliporeSigma, Etobicoke, ON, 
Canada) was used to detect β-actin and rabbit anti-mouse GAPDH antibody (Abcam, 
Cambridge, UK) was used to detect GAPDH.  
 To detect the expression of pMLKL in endothelial cells undergoing necroptosis, 
endothelial cell cultures (in 6-well plates) were subjected to the in vitro cold hypoxia-
reoxygenation injury model described earlier. The reoxygenation phase was limited to 12-18 
hours at which point, the total protein was isolated and analyzed as described earlier. The 
primary antibody used to detect pMLKL was rabbit anti-mouse pMLKL (S345) antibody 
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(Abcam, Cambridge, UK). The primary antibody used to detect MLKL was rat anti-mouse 
MLKL antibody (MilliporeSigma, Etobicoke, ON, Canada).  
2.8 – In Vitro Cold Hypoxia-Reoxygenation Injury Model 
To model ischemia injury, endothelial cell cultures were incubated in oxygen-depleted, 
glucose-free DMEM under hypoxic condition in Whitley H45 Hypoxystation (Don Whitley 
Scientific, United Kingdom) or anaerobic GENbags (BioMérieux, France). For cold hypoxia, 
the Hypoxystation was set at 10°C for 24 hours and the GENbags were placed in a refrigerator 
set at 4°C. To model reperfusion injury, the endothelial cell cultures were removed from the 
hypoxic environment and the oxygen-depleted, glucose free DMEM was replaced with normal 
cell culture medium in a normoxic incubator. Human TNFα (hTNFα; PeproTech, Rocky Hill, 
NJ, USA) at 50-100 μg/mL and recombinant mouse IFNγ (PeproTech, Rocky Holl, NJ, USA) 
at 50-100 μg/mL were added during both the hypoxia and the reoxygenation phases to simulate 
the IRI microenvironment in vitro. Pan-caspase inhibition was achieved by adding the pan-
caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone (z-VAD-
fmk; BD Biosciences, Mississauga, ON, Canada) at 30 μM. RIPK1 inhibition was achieved by 
adding the RIPK1 specific kinase inhibitor necrostatin-1s (Nec-1s; Merck Millipore, 
Etobicoke, ON, Canada) at 10 μM. CypD mediated mPTP formation was inhibited by 
Cyclosporin A (CsA; Sigma-Aldrich, Oakville, ON, Canada) at 0.5-20 μM. The 
immunosuppressive FK-506 (Sigma-Aldrich, Oakville, ON, Canada), which is a calcineurin 
inhibitor but not a CypD inhibitor was used as CsA control. The ROS scavengers used include 
the superoxide dismutase mimetic 1-oxyl-2,2,6,6-tetramethyl-4-hydroxypiperidine 
(TEMPOL; Sigma-Aldrich, Oakville, ON, Canada) at 5-20 μM, the glutathione precursor N-
acetyl-L-cysteine (NAC; Sigma-Aldrich, Oakville, ON, Canada) and the mitochondrion-
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specific superoxide dismutase mimetic mito-TEMPOL (Sigma-Aldrich, Oakville, ON, 
Canada) at 5-20 μM. To inhibit Drp1-mediated mitochondrial division, the Mitochondrial 
Division Inhibitor 1 (Mdivi-1; Sigma-Aldrich, Oakville, ON, Canada) was used at 10-40 μM. 
The CypA inhibitor, Alisporivir (DebioPharm, Lausanne, Switzerland) was used at 0.25-4 μM 
to prevent AIF translocation. Based on available literature and dose-response curves indicating 
maximum reduction in hypoxia/reoxygenation-induced cell death, a dose of 1 μM for 
Alisporivir was chosen for the study. The PARP-1 inhibitor, 3-aminobanzamide (3-ABA; 
MilliporeSigma, Etobicoke, ON, Canada) at 10-100 μM was used to inhibit parthanatos. The 
inhibitors were added during both the hypoxia and the reoxygenation phases. Endothelial cells 
from CypD-/- mice and AIF-silenced endothelial cells were also subjected to the in vitro cold 
hypoxia-reoxygenation injury model.  
2.9 – Cell Death Assay 
Cell death was detected and quantified by real-time imaging in the IncuCyte ZOOM® 
Live Cell Analysis System (Essen Bioscience, Ann Arbor, MI, USA). SYTOX™ Green 
Nucleic Acid Stain (Thermo Fisher Scientific, Mississauga, ON, Canada) at 100 nM was used 
to indicate dead cells. SYTOX™ Green is impermeable to live cells but crosses the 
compromised plasma membranes of dead cells and stains the nucleic acid. It is excited with 
488 nm laser light in the IncuCyte and fluoresces green which helps in distinguishing dead 
cells from live cells. Cell death was also detected with propidium iodide (PI) or annexin V 
labeling (BD Bioscience, Mississauga, ON, Canada) and analyzed by flow cytometry 
(Beckman Coulter, Mississauga, ON, Canada). 
2.10 – Immunocytochemistry  
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To show AIF translocation to the nucleus from the mitochondria in endothelial cells 
undergoing necroptosis, endothelial cell cultures (in 96-well plates) were subjected to the in 
vitro cold hypoxia-reoxygenation injury model described earlier. The reoxygenation phase was 
limited to 24 hours at which point, the cells were fixed with 4% paraformaldehyde in PBS (pH 
7.4) for 30 minutes at room temperature. The cells were washed 3X for 5 minutes each time 
with PBS and then incubated with 0.1-0.25% Triton  X-100 non-ionic surfactant in PBS for 
10 minutes at room temperature for permeabilization. The cells were washed again 3X for 5 
minutes each time with PBS. To reduce non-specific antigen binding and background 
fluorescence, the cells were incubated in a blocking solution (1% BSA, 22.52 mg/mL glycine 
and 0.1% Tween 20) for 30-45 minutes at room temperature. Following blocking, the cells 
were incubated with primary rabbit anti-mouse AIF antibody diluted in 1% BSA in PBS with 
0.1% Tween-20 at 1:1000 concentration ratio for 1 hour at room temperature in a humidified 
chamber. The cells were then washed 3X for 5 minutes each time and then incubated with 
secondary donkey anti-rabbit PE-conjugated antibody (Abcam, Cambridge, United Kingdom) 
diluted in 1% BSA in PBS at 1:60 concentration ratio for 1 hour at room temperature in a dark 
humidified chamber. The cells were washed again 3X for 5 minutes each time with PBS. For 
nuclear counterstaining, the cells were incubated with 300 nM DAPI staining solution (Thermo 
Fisher Scientific, Mississauga, ON, Canada) for 5 minutes at room temperature in a humidified 
chamber and then washed 3X for minutes each time with PBS. Nikon Inverted Research 
Microscope ECLIPSE Ts2R (Nikon, Tokyo, Japan) was used to capture fluorescent images at 
20-40X magnification.  
2.11 – DNA Gel Analysis 
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To analyze AIF-mediated DNA degradation into ~50 kbp fragments, endothelial cell 
cultures (in 6-well plates) were subjected to the in vitro cold hypoxia-reoxygenation injury 
model described earlier. The reoxygenation phase was limited to 12-18 hours at which point, 
DNA was isolated using the Qiagen Blood & Cell Culture DNA Mini Kit (Qiagen, Hilden, 
Germany). The concentration and purity of the isolated DNA was measured using the 
NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, Mississauga, ON, Canada). 
The size of the isolated DNA fragments was characterized by electrophoretic separation using 
0.3% agarose gel run at 3-4 V/cm. For DNA visualization, the agarose gel was stained with 
SYBR™ Safe DNA Gel Stain and imaged in the FluorChem M Imaging System.  
2.12 – Statistical Analysis  
The experimental values are expressed as mean ± SD. Data was analyzed using the 
Student’s t-test for unpaired values, and 1- and 2-way ANOVA with Tukey’s post-hoc 
corrections test. The Mantel-Cox Log Rank test was used to determine graft survival 
differences. Differences were considered significant when p-value ≤ 0.05.
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Chapter 3 
RESULTS 
3.1 – In Vitro Cold Hypoxia-Reoxygenation Injury Promotes Necroptosis in 
Endothelial Cells 
Endothelial cells from WT B6 mice were isolated and subjected to the in vitro cold 
hypoxia-reoxygenation injury model described earlier. TNFα, IFNγ, z-VAD-fmk and Nec-1s 
were added during the hypoxia as well as the reperfusion phases. Murine TNFα (mTNFα) can 
bind to both TNF-R1 and TNF-R2 [225, 226, 227]. While TNF-R1 signaling induces cell death, 
TNF-R2 signaling promotes cell survival [223, 224]. To ensure signaling through the TNF-R1, 
human TNFα (hTNFα) was used, which specifically binds to murine TNF-R1 (with limited 
TNF-R2 binding) [225, 226, 227]. SYTOX™ Green staining was used to indicate and measure 
cell death in the IncuCyte. Treatment of endothelial cells with the proinflammatory cytokines 
hTNFα and IFNγ increased cell death compared to untreated cells (Figure 9). The addition of 
z-VAD-fmk to hTNFα + IFNγ treated cells increased cell death compared to cells treated only 
with hTNFα + IFNγ. z-VAD-fmk is a pan-caspase inhibitor and prevents apoptosis; therefore, 
the increase in cell death following treatment with z-VAD-fmk was suggestive of necroptosis. 
This was confirmed with the addition of the RIPK1 inhibitor Nec-1s. The addition of Nec-1s 
significantly reversed the cell death observed in the hTNFα + IFNγ + z-VAD-fmk treated cells. 
Cell death during and immediately following the cold hypoxia phase was minimal and 
progressively increased during the reperfusion phase in all treatment groups (Figure 9A). Cell 
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death in the first 36 hours was negligible in the absence of cold hypoxia-reoxygenation injury 
in all treatment groups 
 
 
 
 
 
 
 
. 
51 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B
A 
52 
 
Figure 9 – Cold Hypoxia-Reoxygenation Injury Promotes Necroptosis in Endothelial 
Cells 
(A) WT B6 endothelial cells were seeded in a 96-well plate in triplicates at 70-80% confluency. 
To model in vitro ischemia injury, endothelial cell cultures were incubated in oxygen-depleted, 
glucose-free DMEM during hypoxia. The cell culture plates were subjected to cold hypoxia 
for 24 hours in anaerobic GENbags placed in a refrigerator set at 4°C. To model in vitro 
reperfusion injury, the endothelial cell cultures were removed from the hypoxia environment 
and the oxygen-depleted, glucose free culture medium was replaced with normal cell culture 
medium before the endothelial cell cultures were transferred to a normoxic incubator set at 
37°C, 20% O2 and 5% CO2. hTNFα (T) at 100 μg/mL, IFNγ (I) at 100 μg/mL, z-VAD-fmk (Z) 
at 30 μM and Nec-1s (N) at 10 μM were added during both the hypoxia and the reoxygenation 
phases to simulate the IRI microenvironment in vitro. SYTOX™ Green Nucleic Acid Stain at 
100 nM was used as a nuclear counterstain to indicate dead cells. Cell death (during the 
reoxygenation phase; time in hours on X-axis represents reoxygenation time following 24 
hours of cold hypoxia at 4°C) was detected and quantified in the IncuCyte ZOOM® Live Cell 
Analysis System. For positive control, 1% Triton  X-100 (Tx100) non-ionic surfactant was 
used to induce 100% cell death and used to calculate percent cell death in all the treatment 
groups. (B) Data at 36 hours post-reperfusion are shown as mean ± SD and representative of 
at least 3 independent experiments; n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-
significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test.  
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3.2 – PGAM5-Drp1 Axis and ROS Do Not Contribute to 
Hypoxia/Reoxygenation-Induced Necroptosis in Endothelial Cells 
The potential mitochondrial mediators of necroptosis include the PGAM5-Drp1 axis 
and ROS [106, 115, 116, 117, 118, 119, 123, 124]. ROS are also generated following mPTP 
formation [13, 18, 20, 106, 125, 127]. To determine the role of the PGAM5-Drp1 axis in 
necroptosis, the Drp1 inhibitor, Mdivi-1, was used. The addition of Mdivi-1 to hTNFα + IFNγ 
+ z-VAD-fmk treated cells did not reverse the hypoxia/reoxygenation-induced necroptosis 
(Figure 10A). This finding ruled out the role of the PGAM5-Drp1 axis in endothelial cell 
necroptosis following cold hypoxia-reoxygenation injury.  
The generation of ROS and ROS-mediated injury have been the most crucial focus of 
basic and clinical research studies aimed at understanding the molecular mechanisms of 
reperfusion injury. The role of ROS-mediated cellular injury in inducing apoptosis in the 
setting of IRI has been extensively documented [13, 18, 110, 111, 112, 113, 114]. As explained 
earlier, the role of ROS in inducing necroptosis has been studied in several cell types following 
various types of injuries but particularly IRI [102, 103, 104, 105, 106, 109, 154, 156, 157, 158, 
194, 195, 196]. These studies, however, have yielded conflicting results indicating that the role 
of ROS in necroptosis is dependent on cell-type and the cause of injury.  
To determine the role of ROS in hypoxia/reoxygenation-induced necroptosis in 
endothelial cells, the ROS scavengers, TEMPOL and NAC were used. The addition of 
TEMPOL or NAC to hTNFα + IFNγ + z-VAD-fmk treated cells did not reverse necroptosis 
following the in vitro cold hypoxia-reoxygenation injury (Figure 10B&C). The addition of the 
mitochondrion-specific ROS scavenger, mito-TEMPOL, to hTNFα + IFNγ + z-VAD-fmk 
treated cells also did not reverse the hypoxia/reoxygenation-induced necroptosis (Figure 10D). 
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This finding ruled out the role of ROS in hypoxia/reoxygenation-induced necroptosis in 
endothelial cells. It also established that mitochondrial ROS (following mPTP formation and 
ETC dysfunction) did not contribute to hypoxia/reoxygenation-induced necroptosis in 
endothelial cells.  
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Figure 10 – PGAM5-Drp1 Axis and ROS Do Not Contribute to Hypoxia/Reoxygenation-
Induced Necroptosis in Endothelial Cells 
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation model and 
cell death was detected and quantified as described earlier in Figure 9. Data at 36 hours post-
reperfusion are shown as mean ± SD and representative of at least 3 independent experiments. 
(A) Drp1 inhibitor – Mdivi-1 at 10 μM, 20 μM and 40 μM was added during both the hypoxia 
and the reoxygenation phases to inhibit PGAM5-Drp1-induced mitochondrial fragmentation. 
n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way 
ANOVA; Tukey’s multiple comparisons test. (B) ROS scavenger – TEMPOL at 5 μM, 10 μM 
and 20 μM was added during both the hypoxia and the reoxygenation phases to inhibit ROS-
mediated cell damage and death. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-
significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test. (C) ROS 
scavenger – NAC at 5 μM, 10 μM and 20 μM was added during both the hypoxia and the 
reoxygenation phases to inhibit ROS-mediated cell damage and death. n = 3; ***p ≤ 0.001, 
**p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s 
multiple comparisons test. (D) Mitochondrion-specific ROS scavenger – mito-TEMPOL at 5 
μM, 10 μM and 20 μM was added during both the hypoxia and the reoxygenation phases to 
inhibit mitochondrial ROS-mediated cell damage and death. n = 3; ***p ≤ 0.001, **p ≤ 0.002, 
*p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple 
comparisons test. 
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3.3 – CypD-Mediated mPTP Formation Contributes to Hypoxia/Reoxygenation-
Induced Necroptosis in Endothelial Cells 
As described earlier, studies have firmly established the role of CypD in regulating 
mPTP formation [20, 125, 137, 138, 142]. Of the putative mitochondrial mediators involved 
in necroptosis, the role of CypD-mediated mPTP formation is the most well-studied. As with 
ROS, studies investigating the role of CypD-mediated mPTP in necroptosis have yielded 
contradictory results [104, 106, 128, 132, 133, 134, 135, 136]. Persistent/prolonged mPTP 
formation leads to the incomplete reduction of oxygen and also provides a link to ROS 
generation, which lead to cellular damage, are a strong trigger for necroptosis and are 
investigated as the downstream mediators of necroptosis [13, 18, 20, 104, 106, 140, 141].   
To study the role of CypD in hypoxia/reoxygenation-induced necroptosis in endothelial 
cells, CsA was used. CsA is a potent CypD inhibitor and blocks mPTP formation [13, 18, 20, 
104, 137, 138, 211]. As with Nec-1s, the addition of CsA to hTNFα + IFNγ + z-VAD-fmk 
treated cells reversed the hypoxia/reoxygenation-induced necroptosis in endothelial cells 
(Figure 11A). Besides, blocking mPTP formation, CsA is a calcineurin inhibitor and a potent 
immunosuppressive drug [211, 212]. To rule out the participation of calcineurin in necroptosis, 
the non-CypD binding calcineurin inhibitor, FK-506, was used [104, 211]. The addition of FK-
506 to hTNFα + IFNγ + z-VAD-fmk treated cells did not inhibit hypoxia/reoxygenation-
induced necroptosis in endothelial cells.  
Phosphorylation of MLKL is an established event in necroptosis [102, 104, 105, 106]. 
In the hTNFα + IFNγ + z-VAD-fmk treated cells, which were undergoing 
hypoxia/reoxygenation-induced necroptosis, pMLKL protein expression was noted (Figure 
11B&C). The addition of Nec1s to the hTNFα + IFNγ + z-VAD-fmk treated cells, significantly 
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reduces the level of hypoxia/reoxygenation-induced necroptosis and the level of pMLKL 
protein expression (Figure 11B&C). 
To confirm the role of CypD in necroptosis, endothelial cells from CypD-/- mice were 
subjected to the in vitro cold hypoxia-reoxygenation injury model. As with CypD inhibition 
by CsA, CypD-/- endothelial cells resisted hypoxia/reoxygenation-induced necroptosis (Figure 
11D). In our study, the level of necroptosis inhibition by Nec-1s is comparable to the level of 
necroptosis inhibition by CypD inhibition and ablation (Figure 11A&D). This finding confirms 
that CypD contributes to hypoxia/reoxygenation-induced necroptosis in endothelial cells. 
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Figure 11 – CypD Deficiency Prevents Hypoxia/Reoxygenation-Induced Necroptosis in 
Endothelial Cells 
WT and CypD-/- B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation 
model and cell death was detected and quantified as described earlier in Figure 9. Data at 36 
hours post-reoxygenation are shown as mean ± SD and representative of at least 3 independent 
experiments. (A) CypD inhibitor – CsA at 10 μM was added during both the hypoxia and the 
reoxygenation phases. For control, the non-CypD binding calcineurin inhibitor FK506 at 10 
μM was during both the hypoxia and the reoxygenation phases. n = 3; ***p ≤ 0.001, **p ≤ 
0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple 
comparisons test. CsA dose (10 μM) was optimized (dose-response curves showing maximum 
reduction in cell death following cold hypoxia-reoxygenation injury) after using it at various 
concentrations from 0.5-20 μM; corresponding doses were used for FK506. (B) WT 
endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model 
described earlier in Figure 9. The reoxygenation phase was limited to 12-15 hours, at which 
point the total protein was isolated and Western Blot analysis was performed for detection of 
pMLKL protein. GAPDH was used as loading control. (C) The level of pMLKL protein 
expression was quantified in the TIZ and TIZN groups. n = 3; **p ≤ 0.05; Student’s t test for 
paired values. (D) Endothelial cells were isolated from CypD-/- mice and were subjected to the 
same in vitro cold hypoxia-reoxygenation injury model. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p 
≤ 0.033, ns = non-significant (p value ≥ 0.05); 2-way ANOVA; Tukey’s multiple comparisons 
test. 
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3.4 – AIF Contributes to Hypoxia/Reoxygenation-Induced Necroptosis in 
Endothelial Cells 
Necroptosis exhibits morphological features of unregulated necrosis. Characteristic 
findings of necroptotic death include cell membrane rupture and permeabilization, oncosis and 
vacuolization of the cytoplasm and organelles, mitochondrial swelling and DNA fragmentation 
[102, 105, 109, 110, 157]. Extra-mitochondrial AIF translocates to the nucleus and induces 
caspase-independent cell death by inducing large-scale DNA fragmentation (~50 kbp 
fragments) [147, 148]. AIF-mediated DNA degradation has been shown to occur in response 
to several types of pathologic insults, including IRI [145, 146, 147, 148, 173, 174, 175, 176, 
177, 178]. Recent studies have also indicated that mPTP formation facilitates AIF release from 
the mitochondria by serving as a morphological conduit [145, 177]. Therefore, we decided to 
investigate the role of AIF in hypoxia/reoxygenation-induced necroptosis in endothelial cells 
using the in vitro cold hypoxia-reoxygenation injury model.  
To date, no effective pharmacological inhibitor of AIF has been recognized [147, 148]. 
Therefore, to study the role of AIF in hypoxia/reoxygenation-induced necroptosis in 
endothelial cells, Aifm1 was silenced in WT B6 endothelial cells using siRNA. AIF silencing 
was confirmed by RT-qPCR and Western Blot (Figure 12). AIF-silenced endothelial cells were 
subjected to the in vitro cold hypoxia-reoxygenation injury model. Compared to scrambled 
siRNA-transfected endothelial cells, AIF-silenced endothelial cells show a significant 
reduction in cell death in all treatment groups, indicating inhibition of necroptosis in the AIF-
silenced cells. The level of cell death in the AIF-silenced hTNFα + IFNγ + z-VAD-fmk group 
is similar to the level of cell death in the WT hTNFα + IFNγ + z-VAD-fmk + Nec-1s group 
(Figure 13A). This finding indicates that AIF has a critical role in the necroptotic pathway. 
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Recent studies have established that AIF translocation to the nucleus requires CypA 
and is inhibited by HSP-70 [147, 148, 152]. Since there are no known AIF inhibitors, CypA 
inhibition can be used to indirectly evaluate the role of AIF. Alisporivir is a non-
immunosuppressive cyclophilin binding molecule that binds to CypA, an essential co-factor 
for Hepatitis C virus replication [221, 222]. Several in vitro and in vivo studies have explored 
the therapeutic potential of Alisporivir in patients with chronic hepatitis C viral infection [148, 
221, 222]. To evaluate the role of AIF in hypoxia/reoxygenation-induced necroptosis in 
endothelial cells, we used Alisporivir. The addition of Alisporivir to the hTNFα + IFNγ + z-
VAD-fmk treatment group considerably reduces the level cell death in WT endothelial cells 
following the in vitro cold hypoxia-reoxygenation injury (Figure 13B). This finding establishes 
that AIF has a critical role in hypoxia/reoxygenation-induced necroptosis in endothelial cells.  
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Figure 12 – siRNA-Induced Silencing of Aifm1 
WT B6 endothelial cells were transfected with 200 nM ON-TARGETplus Mouse Aifm1 using 
EndoFectin™ Max transfection reagent in Opti-MEM® media. Transfected cells were 
harvested for in vitro cold hypoxia-reoxygenation injury experiments at 48 hours post-
transfection. (A) siRNA-induced silencing of Aifm1 was confirmed by RT-qPCR at 48 hours 
post-transfection. β-actin was used as endogenous control for gene expression analysis. Data 
at 48 hours post-transfection are shown as mean ± SD and representative of 3 independent RT-
qPCR experiments. n = 3; **p ≤ 0.05; Student’s t test for paired values. (B) The reduction in 
the protein expression of AIF-silenced cells was confirmed by Western Blot analysis at 72 
hours post-transfection. β-actin was used as loading control. (C) The reduction in the level of 
AIF protein expression at 72 hours following siRNA-induced silencing of Aifm1 was measured 
in 3 independent experiments. n = 3; **p ≤ 0.05; Student’s t test for paired values.  
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Figure 13 – AIF Silencing Prevents Hypoxia/Reoxygenation-Induced Necroptosis in 
Endothelial Cells 
WT, scrambled siRNA-transfected cells and AIF-silenced (Aifm1 siRNA-transfected) B6 
endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model and 
cell death was detected and quantified as described earlier in Figure 9. Data at 36 hours post-
reperfusion are shown as mean ± SD and representative of at least 3 independent experiments. 
(A) Scrambled siRNA-transfected and AIF-silenced B6 endothelial cells were harvested 48 
hours post-transfection and subjected to the in vitro cold hypoxia-reoxygenation injury model. 
n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 2-way 
ANOVA; Tukey’s multiple comparisons test. (B) CypA inhibitor – Alisporivir at 1 μM was 
added during both the hypoxia and the reoxygenation phases to inhibit CypA-mediated AIF 
translocation to the nucleus. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant 
(p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test. 
 
 
 
 
 
 
 
67 
 
3.5 – AIF Translocation to the Nucleus in Hypoxia/Reoxygenation-Induced 
Necroptosis in Endothelial Cells 
 Following its release into the cytosol from the mitochondria, AIF translocates to the 
nucleus and induces DNA degradation [147, 148]. To confirm the role of AIF in necroptosis, 
WT endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model 
and immunocytochemistry was used to observe AIF translocation to the nucleus in various 
treatment groups. In untreated cells, AIF localizes to the mitochondria in the cytoplasm (Figure 
14). AIF translocation to the nucleus is observed in the hTNFα + IFNγ and hTNFα + IFNγ + 
z-VAD-fmk treatment groups. AIF translocation and overall cell death (necroptosis) is 
considerably reduced in the hTNFα + IFNγ + z-VAD-fmk + Nec-1s and hTNFα + IFNγ + z-
VAD-fmk + Alisporivir treatment groups (Figure 14). Inhibition of AIF translocation to the 
nucleus following treatment with Nec-1s indicates that AIF is the downstream mitochondrial 
mediator involved in hypoxia/reoxygenation-induced necroptosis in endothelial cells. 
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Figure 14 – AIF Translocation to the Nucleus in Hypoxia/Reoxygenation-Induced 
Necroptosis in Endothelial Cells 
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury 
model described earlier in Figure 9. Alisporivir at 1 μM was added during both the hypoxia 
and the reoxygenation phases. The reoxygenation phase was limited to 24 hours at which point 
the cells were fixed with 4% formaldehyde solution and permeabilized with 0.1-0.25% 
Triton  X-100 non-ionic surfactant. To reduce non-specific antigen binding and background 
fluorescence, the cells were incubated with a blocking solution comprised of 1% BSA, 22.52 
mg/mL glycine and 0.1% Tween 20 in D-PBS. The cells were incubated with primary rabbit 
anti-murine AIF antibody diluted in 1% BSA in D-PBS with 0.1% Tween 20 at 1:1000 
concentration ratio for 1 hour at room temperature in a humidified chamber. The cells were 
then incubated with secondary donkey anti-rabbit PE-conjugated antibody diluted in 1% BSA 
in D-PBS at 1:60 concentration ratio for 1 hour at room temperature in a dark humidified 
chamber for immunofluorescence. For DAPI counterstaining, the cells were incubated with 
300 nM DAPI staining solution for 5 minutes at room temperature in a humidified chamber. 
Nikon Inverted Research Microscope ECLIPSE Ts2R was used to capture images at 20-40X 
magnification. (A) Representative individual cell images at 80X magnification are shown. 
Cells undergoing hypoxia/reoxygenation-induced necroptosis (hTNFα + IFNγ + z-VAD-fmk 
treatment group) are shown. (B) Representative microscopic field images at 40X magnification 
are shown. All treatment groups are shown.  
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3.6 – AIF Induces Large-Scale DNA Degradation in Hypoxia/Reoxygenation-
Induced Necroptosis in Endothelial Cells 
To further confirm the role of AIF in hypoxia/reoxygenation-induced necroptosis, WT 
endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury model and 
DNA degradation was characterized by gel electrophoresis. A distinct ~50 kbp band is 
observed in the hTNFα + IFNγ + z-VAD-fmk treatment group. The intensity of the 50 kbp 
band is considerably decreased in the hTNFα + IFNγ + z-VAD-fmk + Nec-1s and hTNFα + 
IFNγ + z-VAD-fmk + Alisporivir groups (Figure 15). This finding indicates that 
hypoxia/reoxygenation-induced necroptosis in endothelial cells involves AIF-mediated DNA 
degradation into ~50 kbp fragments.  
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Figure 15 – AIF Induces Large-Scale DNA Degradation During Hypoxia/Reoxygenation-
Induced Necroptosis in Endothelial Cells 
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation injury 
model described earlier in Figure 9. Alisporivir at 1 μM was added during both the hypoxia 
and the reoxygenation phases. The reoxygenation phase was limited to 12-18 hours at which 
point, DNA was isolated using the QIAGEN Blood & Cell Culture DNA Mini Kit. The size of 
the isolated DNA fragments was characterized by electrophoretic separation using 0.3% 
agarose gel run at 3-4 V/cm.  
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3.7 – Parthanatos Does Not Contribute to Hypoxia/Reoxygenation-Induced 
Endothelial Cell Death  
ROS-mediated oxidative damage to DNA in the setting of IRI induces PARP-1 
activation [106, 149, 180, 181, 182]. PARP-1 activation causes ADP ribosylation of 'damaged' 
chromatin, modulating its structure and facilitating its interaction with DNA repair enzymes. 
However, if the DNA damage is severe, the excessive PAR moieties in the nucleus translocate 
to the mitochondria and mediate AIF release, ultimately leading to a form of regulated necrosis 
termed parthanatos [149]. We investigated the role of parthanatos in endothelial cell death 
using our in vitro cold hypoxia-reoxygenation injury model. The addition of the PARP-1 
inhibitor, 3-ABA to hTNFα + IFNγ + z-VAD-fmk treated cells, did not reverse the 
hypoxia/reoxygenation-induced necroptosis (Figure 16). This indicates that parthanatos does 
not contribute to hypoxia/reoxygenation-induced endothelial cell death. 
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Figure 16 – Hypoxia/Reoxygenation-Induced AIF Release Does Not Contribute to 
Parthanatos 
WT B6 endothelial cells were subjected to the in vitro cold hypoxia-reoxygenation model and 
cell death was detected and quantified as described earlier in Figure 9. PARP-1 inhibitor, 3-
ABA at 10 μM, 50 μM and 100 μM were added during both the hypoxia and the reoxygenation 
phases. Data at 36 hours post-reperfusion are shown as mean ± SD and representative of at 
least 3 independent experiments. n = 3; ***p ≤ 0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-
significant (p value ≥ 0.05); 1-way ANOVA; Tukey’s multiple comparisons test. 
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3.8 – CypD Ablation in Donor Hearts Attenuates IRI-Induced Allograft Injury 
and Promotes Long-Term Graft Survival 
Static cold (4°C) storage is the most commonly used strategy in donor organ 
preservation [218, 219, 220]. Myocardial tissue is particularly sensitive to ischemia, and donor 
heart preservation is limited to 4-6 hours in clinical transplantation [4, 5, 6, 7, 8, 9, 10, 12]. 
Our in vitro data strongly supported the role of CypD inhibition and ablation in protecting 
endothelial cells from hypoxia/reoxygenation-induced necroptosis. We wanted to extend our 
findings to a clinically relevant model of cardiac transplantation. To study the in vivo efficacy 
of CypD ablation in promoting graft survival, donor hearts from WT and CypD-/- B6 mice were 
subjected to ischemic storage at 4°C for 4 hours and then transplanted into BALB/c mice. Our 
data show that ischemia aggravates graft rejection and significantly reduces graft survival time 
compared to non-ischemic grafts (Figure 17A). Interestingly, CypD ablation in donor hearts 
attenuates ischemia-induced rejection and promotes graft survival (Figure 17B).   
Histomorphological evaluation of WT and CypD-/- allografts at 28 days post-
transplantation indicated significant damage to the microvasculature, with neointima formation 
and fibrosis in the WT allografts (Figure 18A&B). These changes indicated severe 
inflammatory damage and were accompanied with T cell and monocyte/macrophage 
infiltration into the graft as assessed by CD3 and CD68 staining (Figure 18C). Allograft injury 
to the microvasculature, inflammatory damage and lymphocyte infiltration into the graft were 
significantly decreased in the CypD-/- allografts (Figure 18D).  
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Figure 17 – CypD Ablation Attenuates IRI-Induced Allograft Injury and Promotes Long-
Term Graft Survival 
Heart grafts from WT and CypD-/- B6 mice were subjected to ischemic storage at 4°C for 4 
hours before being transplanted into BALB/c mice followed by anti-CD40L injection. Graft 
survival was monitored twice a week. Cessation of beating was considered as rejection. (A) 
Ischemia aggravates graft rejection and reduces graft survival time. n = 4; *p ≤ 0.05; Log-Rank 
test. (B) CypD deficiency in donor hearts attenuates ischemia-aggravated graft rejection and 
prolongs graft survival time. n = 4/group; *p ≤ 0.05; Log-Rank test. 
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Figure 18 – CypD Ablation Attenuates IRI-Induced Allograft Injury, Inflammatory 
Damage and Alloimmune Response 
Heart grafts from WT and CypD-/- B6 mice were subjected to ischemic storage at 4°C for 4 
hours before being transplanted into BALB/c mice as described in Figure 17. Recipient mice 
(n = 4/group) were euthanized 28 days post-transplantation and the cardiac allografts were 
isolated, fixed with 10% neutral buffered formalin and embedded in paraffin for sectioning. 
The tissue sections were then stained with H&E, Verhoeff–Van Gieson Elastic Stain and CD3 
& CD68 Immunohistochemistry. Nikon ECLIPSE E200 microscope was used to capture 
images at 20X and 4X magnification. Allograft injury was evaluated and quantified based on 
damage to microvasculature, neointima formation, fibrosis and lymphocytic infiltration 
compared to naïve tissue by a pathologist in a blinded manner. The criteria used scored the 
injury on a scale of 0-4 as follows – 0: no change, 1: 0-24% change, 2: 25-49% change, 3: 50-
74% change, and 4: >75% change. Representative slide images are shown. (A) Hematoxylin 
& Eosin staining of tissue sections from cardiac grafts isolated from WT and CypD-/- mice, 
indicating damage to the endothelium. (B) Elastic staining of tissue sections from cardiac grafts 
isolated from WT and CypD-/- mice, indicating damage to the microvasculature. (C) CD3 and 
CD68 Immunohistochemistry of tissue sections from cardiac grafts isolated from WT and 
CypD-/- mice, indicating graft infiltration by T cells and monocytes/macrophages, respectively. 
(D) Quantification of WT and CypD-/- cardiac graft injury in WT and CypD-/- mice, evaluating 
arterial damage, neointima formation, fibrosis and lymphocytic infiltration. n = 3; ***p ≤ 
0.001, **p ≤ 0.002, *p ≤ 0.033, ns = non-significant (p value ≥ 0.05); 2-way ANOVA; Tukey’s 
multiple comparisons test.
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Chapter 4 
DISCUSSION 
4.1 – Study Summary 
A growing body of evidence indicates that necroptosis plays an important role in the 
pathogenesis of numerous clinical conditions and diseases [102, 103, 104, 105, 106, 109, 110]. 
The pathological relevance of necroptosis in the context of organ transplantation is particularly 
significant. Necroptosis is an inflammatory form of cell death that contributes to graft injury 
and triggers alloimmunity, which adversely affects graft survival and function [102, 103, 104, 
105, 109, 110]. Studies by our group have demonstrated the role of necroptosis in inducing 
inflammation and tissue injury in donor heart and kidney grafts [103, 104]. We have previously 
demonstrated that RIPK1 and RIPK3 contribute to necroptosis and that RIPK3 ablation 
attenuates graft rejection [103, 104]. While the upstream pathways of necroptosis are well-
established, the role of mitochondria and the downstream mechanisms involved remain 
controversial [102, 106]. A recent study by our group demonstrated that the downstream 
pathway of necroptosis involves CypD-mediated mPTP formation and that CypD-deficient 
donor hearts exhibit prolonged survival [104].  
 In this study, we investigated the role of necroptosis in cell death induced by cold 
hypoxia-reoxygenation injury, which modeled in vivo IRI. Our data indicate that necroptosis 
plays a significant role in hypoxia/reoxygenation-induced cell death in endothelial cells, 
indicating its relevance in IRI and organ transplantation. Inhibition of caspases prevents 
hypoxia/reoxygenation-induced apoptosis but promotes necroptosis and significantly increases 
overall cell death (Figure 9A&B). We were able to corroborate findings from our previous 
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study indicating the role of CypD in necroptosis using the in vitro cold hypoxia-reoxygenation 
injury model. We found that CypD inhibition (and ablation) significantly attenuates 
hypoxia/reoxygenation-induced necroptosis (Figure 11). We then extended our findings to a 
clinically relevant model of cardiac transplantation. Donor hearts from WT and CypD-/- mice 
were subjected to static cold storage (ischemic injury) followed by heterotopic transplantation 
into BALB/c mice (reperfusion injury). We found that pre-transplant ischemia aggravates 
cardiac allograft rejection and that CypD-/- cardiac allografts survive significantly longer than 
WT cardiac allografts (Figures 17 and 18). Our in vitro and in vivo studies confirmed that 
CypD plays an essential role in the necroptotic pathway and that inhibiting CypD confers 
protection against IRI and attenuates alloimmunity.  
Subsequently, we investigated the roles of various potential mediators downstream of 
CypD-mediated mPTP formation. We first ruled out the roles of ROS (oxidative damage) and 
the PGAM5-Drp1 axis (mitochondrial fragmentation) in hypoxia/reoxygenation-induced 
necroptosis (Figure 10). We observed the translocation of AIF to the nucleus and AIF-mediated 
DNA degradation into ~50 kbp fragments following cold hypoxia-reoxygenation injury 
(Figures 14 and 15). We found that AIF silencing significantly decreases 
hypoxia/reoxygenation-induced necroptosis (Figure 13A). Since no known pharmacological 
inhibitors of AIF exist, we confirmed our results by restricting AIF translocation to the nucleus 
via CypA inhibition, since CypA is required for the translocation of AIF to the nucleus [148, 
152, 153]. CypA inhibition also decreases hypoxia/reoxygenation-induced necroptosis (Figure 
13B). We found that disrupting the upstream pathway of necroptosis via RIPK1 inhibition 
prevents AIF translocation to the nucleus and DNA degradation into ~50 kbp fragments 
(Figures 14 and 15). These findings suggest that AIF may be the downstream mediator in 
necroptosis. 
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4.2 – The Endothelium in Organ Transplantation 
The endothelium is critical in maintaining the vascular homeostasis and constitutes the 
first barrier between the recipient’s immune system and the allograft. Substantial injury to the 
endothelium results in loss of vascular integrity and tone, increased vascular permeability and 
intravascular thromboses, which disrupts blood flow, promotes inflammation and 
alloimmunity and ultimately, contributes to graft injury and necrosis [65, 66, 67, 77, 90, 95, 
96]. Endothelial cells are susceptible to the different forms of PCD induced by IRI [8, 10, 65, 
66, 67, 77, 90, 103, 104]. Given the central role of the endothelium in initiating and promoting 
the alloimmune response, preventing endothelial cell death is particularly important. 
4.3 – Necroptosis in IRI and Organ Transplantation 
IRI is an inevitable consequence of organ transplantation (Figure 1) with life-
threatening consequences in the immediate postoperative period, such as PGD. IRI has also 
been shown to have deleterious long-term effects on graft survival and contributes to graft 
rejection (Figure 3) [4, 8, 12]. Improvements in organ preservation processes and post-
transplantation immunosuppressive protocols have not diminished the impact of IRI on graft 
survival and function; therefore, current research efforts are focused on minimizing IRI itself. 
IRI is associated with unregulated necrosis and various forms of PCD (Figures 2, 4 and 5). A 
thorough understanding of the mechanisms involved in PCD can aid in the designing of 
targeted therapies that disrupt IRI and promote graft survival [8, 12, 13, 18].  
 Historically, apoptosis was considered the sole form of PCD, with essential roles in 
homeostasis, development and numerous disease processes, including IRI. However, evidence 
now indicates that necrosis, which was previously regarded as an unregulated form of cell 
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death, can occur in a regulated manner [102, 105, 154]. There are many different forms of 
regulated necrosis (Figure 4) [101]. Amongst the different forms of regulated necrosis induced 
by IRI, the best characterized and clinically relevant in the context of organ transplantation is 
necroptosis [13, 102, 103, 104, 105, 109, 110, 154, 155, 156, 157, 158]. Necroptosis is a highly 
inflammatory form of cell death that triggers robust alloimmune responses due to the release 
of cDAMPs and cytosolic contents [102, 103, 104, 154, 155, 156, 157, 158]. Thus, inhibiting 
IRI-induced necroptosis will minimize the loss of functional cells and limit the inflammatory 
and alloimmune injuries in organ transplantation [102, 103, 104, 156, 157, 158].  
In a recent study by our group, we showed that endothelial cells are susceptible to 
TNFα-induced necroptosis [104]. Considering the role of endothelial dysfunction in 
augmenting graft injury and promoting alloimmunity, we investigated the role of 
hypoxia/reoxygenation-induced necroptosis in endothelial cells. Our findings indicate that 
necroptosis plays a significant role in hypoxia/reoxygenation-induced endothelial cell death 
and that the inhibition of caspases decreases apoptosis but increases necroptosis and overall 
cell death (Figure 9A). To develop a better understanding of the necroptotic pathway, we 
designed this study to investigate the putative mediators and downstream mechanisms 
activated following the upstream signaling.  
4.4 – Role of Mitochondria in Hypoxia/Reoxygenation-Induced Necroptosis 
In necroptosis, the sequence of events downstream of the RIPK1/RIPK3 necrosome 
formation and phosphorylation of MLKL is a subject of scientific controversy (Figure 5) [102, 
104, 106]. Specifically, the evidence for the role of mitochondria in necroptosis is conflicting 
[102, 104, 106]. While the majority of the studies support a role for mitochondria in 
necroptosis, a few studies suggest that the mitochondria may be dispensable for this process 
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[106]. This was best argued by Tait et al. who showed that widespread mitochondrial depletion 
via mitophagy in SVEC and 3T3 cells did not disrupt necroptosis [128]. One proposed pathway 
that does not involve the mitochondria implicates the translocation of oligomerized pMLKL 
to the plasma membrane, followed by its rupture. Although inconclusive, evidence for this 
pathway was presented by Cai et al. and Chen et al. using multiple cell types [133, 134].  
The earliest studies investigating the downstream mechanisms of necroptosis indicated 
a shift in metabolism leading to ROS production following necrosome translocation to the 
mitochondria (Figure 5) [106].  In a study done by Lin et al. using MEFs, TNFα signaling 
increased ROS levels and necroptosis and the use of the ROS scavenger, butylated 
hydroxyanisole, efficiently blocked necroptosis following TNFα stimulation [115]. 
Furthermore, the ablation of critical necroptotic mediators, RIPK1, TRAF2 and FADD, led to 
decreased ROS levels and resistance against TNFα-induced necroptosis. Vanlangenakker et al. 
later demonstrated that the RIPK1/RIPK3-mediated ROS generation following TNFα 
stimulation in L929 cells were mitochondrially derived [116]. These findings were 
corroborated by Ardestani et al., who used two different cell lines, L929 and RAW 264.7, to 
demonstrate the mitochondrial origin of ROS generated following TNFα stimulation [117]. 
The strongest evidence indicating the role of mitochondrial ROS in necroptosis was provided 
by Davis et al., who showed the translocation of RIPK3 to the mitochondria following TNFα 
stimulation and inhibition of necroptosis with the mitochondrial antioxidant MnSOD in 
endothelial cells [122].  
The earlier studies strongly implicating a role for mitochondrial ROS in necroptosis 
were later disputed by findings from other studies, which indicated that ROS were not 
'absolutely’ essential for necroptosis. He et al. suggested that the downstream mechanism of 
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necroptosis may be cell-type specific [159]. While establishing the role of RIPK3, they showed 
that ROS scavenging in HT-29 cells did not attenuate TNFα-induced necroptosis. This 
observation was supported by a study by Temkin et al., which precluded the role of 
antioxidants (ascorbic acid, glutathione and NAC) in rescuing THP-1 cells from TNFα-induced 
necroptosis [120]. Hence, the role of ROS in mediating necroptosis requires further 
investigation.  
IRI is associated with significant production of ROS, including ROS generated 
secondary to mitochondrial damage and ETC disruption (Figure 2) [13, 18]. We, therefore, 
decided to investigate the role of ROS in hypoxia/reoxygenation-induced necroptosis. In our 
study, treatment with the ROS scavengers, TEMPOL and NAC, did not result in a significant 
reduction of hypoxia/reoxygenation-induced necroptosis (Figure 10 B&C). The use of the 
mitochondria-specific ROS scavenger, mito-TEMPOL, also did not inhibit 
hypoxia/reoxygenation-induced necroptosis (Figure 10D). Although unexpected, our findings 
are not entirely surprising. Endothelial cells have low-energy turnover and generate most of 
their ATP molecules via anaerobic glycolysis [95, 160, 161, 162]. A significant mechanism of 
ROS production following reperfusion injury is associated with ischemia-induced ETC 
dysfunction. While speculative, it is possible that since the endothelial cells rely primarily on 
anaerobic glycolysis, ROS production secondary to ETC dysfunction is minimal and, unlike 
with other cell types, does not contribute to hypoxia/reoxygenation-induced necroptosis in 
endothelial cells.  
Another potential mediator of necroptosis involves the PGAM5-Drp1 axis (Figure 5). 
According to a study by Wang et al., following its formation, the necrosome translocates to 
the mitochondria and interacts with PGAM5. Activated PGAM5, in turn, activates Drp1 and 
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induces mitochondrial fragmentation. Data from this study indicate a direct interaction 
between RIPK1/RIPK3 and PGAM5 indicated by coimmunoprecipitation assays. 
Furthermore, Drp1 silencing and treatment with the PGAM5 inhibitor, MDivi-1, inhibited 
TNFα-induced necroptosis [123]. These findings were later supported by Zhang et al., who 
showed that Drp1 depletion in NRK-52E cells resisted TNFα-induced cell death [124]. Drp1 
inhibition has also been shown to be protective against IRI and recommended as a novel 
therapeutic strategy for cardioprotection [163].  
The role of mitochondrial PGAM5-Drp1 axis has been disputed by recent studies by 
several groups [128, 129, 130, 131]. These studies used PGAM5 and Drp1 silenced or deficient 
MEFs and L929 cells and did not find a reduction in cell death following TNFα stimulation 
[106, 131]. In our study, PGAM5-Drp1 axis inhibition in endothelial cells did not protect 
against hypoxia/reoxygenation-induced cell death (Figure 10A) and ruled out mitochondrial 
fragmentation as the mechanism responsible for cellular demise in hypoxia/reoxygenation-
induced necroptosis. However, a recent study by Zhang et al. suggested that Drp1 modulates 
CypD-mediated mPTP formation and mitochondrial ROS production [163]. It remains to be 
established how this interaction relates to necroptosis.  
We have previously shown that mitochondria critically participate in necroptosis and 
that inhibition of CypD mediated mPTP formation attenuated necroptosis in endothelial cells 
[104]. In this study, we ruled out the role of ROS and PGAM5-Drp1 axis in 
hypoxia/reoxygenation-induced necroptosis and then investigated the role of CypD-mediated 
mPTP formation in hypoxia/reoxygenation-induced necroptosis.   
4.5 – Hypoxia/Reoxygenation-Induced Necroptosis in Endothelial Cells Involves 
CypD-Mediated mPTP Formation 
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The role of CypD-mediated mPTP formation in necroptosis has been the subject of 
considerable study (Figures 2, 4, 5 and 7). In studies conducted by Baines et al., Nakagawa et 
al., and Schinzel et al., CypD-mediated mPTP formation was shown to be involved in 
necroptosis [125, 126, 127]. These studies indicated that CypD ablation provided resistance 
against necroptosis induced by ROS-mediated oxidative damage and mitochondrial calcium 
overload. In the setting of IRI, mPTP formation also provides a link to ROS production. While 
ROS-mediated oxidative damage promotes CypD-mediated mPTP formation by sensitizing 
mPTP to mitochondrial calcium, mPTP formation augments ROS production by contributing 
towards ETC dysfunction and incomplete oxygen reduction [20]. This was confirmed in a 
study by Roca and Ramakrishnan, which showed that TNFα-induced ROS production and 
necroptosis in macrophages were both blocked by CypD inhibition [164].  
As with the other proposed mitochondrial mediators, the role of mPTP formation in 
necroptosis has also been questioned [106, 128]. The most compelling evidence against the 
involvement of mPTP formation in necroptosis was presented in studies by Tait et al., and 
Ch’en et al. [128, 165]. These studies showed that although RIPK1 and RIPK3 ablation 
rescued caspase-8-deficient cells from necroptosis, CypD ablation did not. Linkermann et 
al. also argued against the involvement of mPTP formation by showing that simultaneous 
RIPK3 and CypD ablation provided greater protection against IRI-induced necroptosis than 
separate RIPK3 and CypD depletions [132]. The findings from these studies suggested that the 
proposed necroptotic pathway involving the upstream RIPK1/RIPK3/pMLKL and the 
downstream CypD-mediated mPTP formation pathways were divergent. 
Gan et al. from our group, however, confirmed that the protection conferred by CypD 
ablation is not additive to that conferred by blocking the upstream signaling pathway of 
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necroptosis via RIPK1 inhibition in endothelial cells [104]. Our group also showed that the 
phosphorylation of MLKL, an established event in necroptosis, was suppressed by CypD 
inhibition and ablation. These findings confirmed that CypD-mediated mPTP formation was 
the downstream mechanism involved in TNFα-induced necroptosis in endothelial cells. In this 
study, we found that hypoxia/reoxygenation-induced necroptosis in endothelial cells was 
significantly reversed with CypD inhibition and ablation (Figure 11). Furthermore, the 
protection conferred by CypD inhibition was not additive to that conferred by RIPK1 
inhibition. We, therefore, concluded that hypoxia/reoxygenation-induced necroptosis in 
endothelial cells is dependent on CypD-mediated mPTP formation.  
While inconclusive, recent evidence also implicates CypD-mediated mPTP formation 
in apoptosis (Figure 6). The earliest evidence supporting this position was presented in a study 
by Murphy et al., who showed that the overexpression of the anti-apoptotic protein BCL-2 
suppresses calcium-induced mPTP formation [166]. Later, Crompton et al. and Green et al. 
reported that the use of the CypD inhibitor CsA blocked some forms of apoptosis [167, 168]. 
Most importantly, in its most current model, the OMM component of mPTP is formed by the 
pro-apoptotic proteins BAX and BAD [138, 143]. However, most evidence associating CypD-
mediated mPTP formation to apoptosis is circumstantial and indirect. It is possible that the 
ROS generated secondary to mPTP formation in the setting of cellular injury trigger apoptosis. 
mPTP formation also dysregulates cytosolic calcium homeostasis, which can then activate 
calpains and calcineurin [138, 169]. Calpain-mediated BID cleavage promotes OMM 
permeabilization by BAX and BAK [170]. Similarly, calcineurin activates the pro-apoptotic 
protein BAD, which then antagonizes the anti-apoptotic activities of BCL-2 and BCL-XL 
[171]. Persistent mPTP formation also leads to mitochondrial swelling followed by OMM 
rupture, which may facilitate the release of the pro-apoptotic mediators [13, 18, 20].  
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In order to exclude the role of CypD-mediated mPTP formation in 
hypoxia/reoxygenation-induced apoptosis within this study, we used the pan-caspase inhibitor 
z-VAD-fmk in our in vitro cold hypoxia-reoxygenation injury model. The use of the pan-
caspase inhibitor also indicates that the DNA degradation in necroptosis is not mediated by 
caspase-activated DNases (Figure 9A). In fact, our findings show that inhibition of caspases 
promotes DNA degradation into ~50 kbp fragments. Hence, it is likely that CypD-mediated 
mPTP formation leads to necroptosis without contributing to apoptosis. 
4.6 – Downstream of CypD-Mediated Mitochondrial Damage, 
Hypoxia/Reoxygenation-Induced Necroptosis in Endothelial Cells Involves AIF 
The scientific controversy involving the role of CypD-mediated mPTP formation in 
necroptosis has diverted attention from investigating the precise downstream mechanisms 
activated by its formation. As described earlier, mPTP augments ROS production, the role of 
which was supported by the earlier studies investigating the downstream mechanisms of 
necroptosis (Figure 2) [106, 115, 116, 117, 119, 119]. In this study, our findings suggested that 
the mitochondrial ROS generated secondary to mPTP did not contribute to 
hypoxia/reoxygenation-induced necroptosis since treatment with mito-TEMPOL did not 
confer any protection (Figure 10D). More importantly, however, our findings suggested that 
CypD-mediated mPTP formation was not dependent on ROS since the use of ROS scavengers, 
unlike CypD inhibition, did not attenuate necroptosis. This finding supports a 'direct' link 
between the upstream necroptotic pathway involving RIPK1/RIPK3/pMLKL and CypD-
mediated mPTP formation.  
After excluding the role of ROS and caspases downstream of CypD-mediated mPTP 
formation in hypoxia/reoxygenation-induced necroptosis, we investigated the role of AIF. The 
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dual and apparently paradoxical roles of AIF in cellular life and death can best be compared to 
Cyt C. AIF has an essential survival role as a mitochondrial oxidoreductase involved in the 
assembly and stabilization of the ETC components, Complex I and Complex III [147, 148, 
150]. However, once released into the cytosol, it quickly translocates to the nucleus and 
induces DNA degradation (Figure 8) [145, 146, 147, 148]. Since its discovery by Susin et al. 
20 years ago, several studies have reported the involvement of AIF in various clinical 
conditions and diseases [147, 148]. The role of AIF in IRI is well-established [147, 148, 172, 
173, 174, 175, 176]. Soon after its discovery, Plesnila et al. and Kim et al. published studies 
supporting a role for AIF in cerebral and myocardial IRI-induced cell death, respectively [174, 
175]. Culmsee et al. later demonstrated that compared to WT mice, Hq mice displayed smaller 
infarct volumes and significantly reduced neuronal death after transient cerebral artery 
occlusion [176]. More recent studies have shown the role of AIF in non-ischemic pathological 
conditions as well [145, 146, 147, 148, 172, 177, 178]. 
The mechanism regulating the processing and translocation of AIF to the nucleus is 
complex and not fully understood. The release of AIF from the mitochondria involves two 
essential steps: proteolytic cleavage yielding the truncated 'liberated' form of AIF and 
permeabilization of mitochondria that enables its exit. While not completely established, it is 
speculated that the cleavage of AIF to its liberated form is mediated by cysteine proteases such 
as calpains and cathepsins (Figure 8) [147, 148]. Several studies, including one from the group 
that discovered AIF, have shown that the dissipation of ΔΨm accompanies the release of AIF 
from mitochondria [147, 148, 172]. These studies are supported by experiments in which 
treatment with CsA blocks the release of AIF from the mitochondria suggesting that mPTP 
may be the channel through which AIF is released into the cytosol [145, 177, 178].  
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Our findings from this study clearly support a role for AIF in hypoxia/reoxygenation-
induced necroptosis in endothelial cells. In cells undergoing necroptosis, translocation of AIF 
to the nuclei (Figure 14) and DNA degradation into ~50 kbp fragments was observed (Figure 
15). These changes were associated with the phosphorylation of MLKL, a crucial event in 
necroptosis. Interruption of the upstream necroptotic pathway via RIPK1 inhibition reversed 
these changes. Furthermore, AIF-silenced cells, like CypD-ablated cells, were resistant to 
hypoxia/reoxygenation-induced necroptosis. Our findings, coupled with studies indicating a 
role for mPTP in necroptosis and AIF release, indicate that hypoxia/reoxygenation-induced 
necroptosis in endothelial cells involves the release of AIF from CypD-mediated mPTP 
formation following RIPK1/RIPK3/pMLKL translocation to the mitochondria. While there is 
considerable evidence supporting a role for mPTP in necroptosis and studies suggesting its role 
in the release of AIF, our findings connecting the established upstream pathway of necroptosis 
involving RIPK1/RIPK3/pMLKL to AIF release via CypD-mediated mPTP formation is novel. 
Genomic stress leading to PARP-1 activation has been strongly implicated in various 
diseases [149, 179]. In the setting of IRI, ROS-mediated oxidative damage to DNA and 
subsequent activation of PARP-1 has been reported in various tissues, including the brain, 
heart, intestine and retina [149, 179, 180, 181, 182]. PARP-1 activation causes ADP 
ribosylation of 'damaged' chromatin, modulating its structure and facilitating its interaction 
with DNA repair enzymes. However, if the DNA damage is severe, the excessive PAR 
moieties in the nucleus translocate to the mitochondria and mediate AIF release, ultimately 
leading to a form of cell death termed parthanatos (Figure 4) [147, 149]. 
In this study, neither treatment with the ROS scavengers nor PARP-1 inhibition 
decreased hypoxia/reoxygenation-induced cell death (Figure 16). This finding indicated that 
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the ROS-mediated DNA damage following cold hypoxia-reoxygenation injury, if present, was 
not sufficiently severe to induce the accumulation of excessive PAR moieties in the nucleus. 
The failure to attenuate cell death with direct inhibition of PARP-1 confirmed that the AIF 
release following cold hypoxia-reoxygenation injury was unrelated to PARP-1 activation and 
parthanatos. While targeting AIF to disrupt necroptosis is a promising prospect, it presents two 
problems. Firstly, no pharmacological inhibition of AIF currently exists, and secondly, AIF 
has an essential pro-survival role in cellular bioenergetics. The translocation of AIF to the 
nucleus is facilitated by CypA and suppressed by HSP-70 [147, 148, 172]. As with the 
silencing of AIF, CypA inhibition protected endothelial cells from hypoxia/reoxygenation-
induced necroptosis. Our findings showed that CypA inhibition blocked AIF translocation to 
the nucleus and DNA degradation into ~50 kbp fragments. CypA inhibition, therefore, 
represents an effective therapeutic strategy to disrupt AIF-mediated necroptosis. Our findings 
are supported by recent studies indicating a protective role for CypA inhibition in IRI [147, 
148, 153, 172, 183].   
4.7 – CypD Ablation Attenuates Cardiac Allograft Injury and Transplant 
Rejection 
CypD inhibition has been shown to protect against IRI and neurodegenerative 
disorders. The protection conferred by pharmacological inhibition of CypD against IRI has 
been confirmed with CypD ablation in every organ tested, including heart, kidneys, intestine 
and liver [18, 137, 138, 141, 184, 185, 186, 187, 188, 189, 190, 191, 192]. Inhibition of CypD-
mediated mPTP formation underlies the cardioprotection elicited by the endogenous 
phenomenon of ischemic conditioning and has been recommended as a potential therapeutic 
target in the management of myocardial infarction [184, 185]. These studies strongly indicate 
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that CypD-mediated mPTP formation can be used as an effective strategy in organ preservation 
as well. More recently, Tran et al. have shown that mPTP formation promotes endothelial cell 
immunogenicity in the setting of IRI that can be negated by CypD inhibition [193]. While their 
study focuses on the role of mPTP formation in transplant immunity, it is plausible that the 
increase in endothelial cell immunogenicity is the result of necroptotic cell death. Our group 
has previously shown that interrupting necroptosis via RIPK3 ablation attenuates allograft 
injury and transplant rejection in cardiac and renal transplantation models [103, 104]. CypD 
deficiency in donor hearts conferred the same protection [104]. 
In this study, we extended our findings to a clinically relevant model of donor heart 
preservation involving cold ischemic storage followed by transplantation. Our findings showed 
that pre-transplant ischemia aggravates cardiac allograft rejection. Donor hearts subjected to 
ischemia had shorter survival times compared to non-ischemic hearts (Figure 17A). 
Interestingly, CypD deficiency in donor hearts attenuated graft rejection and promoted 
allograft survival dramatically (Figure 17B). 
4.8 – Therapeutic Strategies to Disrupt Necroptosis 
Pharmacological and genetic inhibition of necroptosis has been shown to ameliorate 
several diseases with an inflammatory component [102, 105, 194, 195, 196]. The first 
pharmacological inhibitor investigated for use in clinical practice was Nec-1, an allosteric 
inhibitor of RIPK1 [102, 197, 198]. However, limited half-life, poor pharmacokinetic 
properties and off-target activity precluded its use [102, 197, 199, 200, 201, 202, 203]. 
Optimization of Nec-1 generated Nec-1s, which enhanced its specificity, but the poor 
pharmacokinetic properties associated with Nec-1 persist and a clinical trial is yet to be 
completed [102, 197, 200, 203]. The newer RIPK1 kinase inhibitors developed by 
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GlaxoSmithKline, including GSK'963 and GSK'2982772, have shown efficacy against 
necroptosis in human cells [204, 205, 206]. However, the results were not replicated in mouse 
and rat cells, limiting explorations of their in vivo therapeutic value with animal disease models 
[206]. RIPK3 kinase inhibitor GSK'872 and MLKL inhibitor necrosulfonamide have also been 
developed, but in vivo data using animal models are lacking [206, 207, 208, 209, 210]. The 
interconnected pathways involving the various forms of PCD and essential cellular functions 
is a limiting factor in the use of all these drugs [197, 203, 206].  
Since it was first discovered in 1972, the CypD inhibitor CsA has been crucial in 
achieving improved survival rates in patients following organ transplantation [211, 212]. While 
the current use of CsA in the post-transplantation setting is aimed at suppressing the immune 
system by repressing the IL-2 -mediated activation of T cells, it is possible that the beneficial 
effects of CsA in organ transplantation involves its inhibitory effect on CypD and prevention 
of mPTP formation [104, 211, 212]. In fact, although the immunosuppressive capacity of CsA 
is less potent than other immunosuppressive agents such as tacrolimus, mycophenolate-mofetil 
and rapamycin, it provides greater protection against graft loss compared to these compounds 
[211, 213, 214, 215, 216, 217]. As with several other studies, findings from this study have 
shown that the use of CsA in organ transplantation results in a reduced inflammatory response 
and significantly improved graft survival and function. Our study is unique because we have 
provided evidence indicating that this is due to the reduction in cell death via the highly 
inflammatory necroptotic death pathway. A more intriguing challenge with the use of CsA (or 
alternative pharmacological agents) to block necroptosis in organ transplantation is its targeted 
and sustained delivery to the donor organ [211]. 
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In this study, inhibiting AIF translocation to the nucleus provided a more significant 
benefit than inhibiting CypD-mediated mPTP formation with CsA. This might be due to the 
presence of an AIF splice-variant located outside the mitochondria that is equally capable of 
translocating to the nucleus and inducing DNA degradation as the mitochondrial AIF [147, 
148]. Inhibition of AIF translocation targets both the mitochondrial and the extra-
mitochondrial AIF, while the use of CsA prevents only the mitochondrial AIF from 
translocating to the nucleus. Although more extensive testing needs to be done, our data explain 
why Hq mice show resistance against IRI [147, 148, 152, 153, 172, 173, 174, 175, 176]. Since 
AIF deficiency is associated with severe adverse effects, a better approach would be inhibition 
of AIF translocation to the nucleus with the use of pharmacological agents such as Alisporivir. 
Inhibition of AIF translocation may promote graft survival and attenuate alloimmunity by 
inhibiting necroptosis while preserving the vital functions of AIF. As such, it represents a 
potent therapeutic strategy in organ transplantation.  
More recently, research investigating better organ preservation strategies have gained 
a lot of attention [218, 219]. This includes the development of perfusion systems and the 
‘engineering’ of organ preservation solutions to enhance the functional preservation of donor 
organs [218, 219, 220]. Our in vitro data from this study showed that combined intervention 
strategies during the hypoxia and reperfusion phases conferred greater protection than 
intervention at any one stage. For this study, our in vivo experiments used the current model of 
organ preservation involving static cold storage. It would be interesting to evaluate the efficacy 
of CsA and Alisporivir in preserving graft viability when used as pharmacological additives in 
organ preservation solutions used in perfusion pumps.  
4.9 – Future Directions 
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Our in vitro data shows the role of AIF in inducing necroptosis in endothelial cells 
following cold hypoxia-reoxygenation injury. We are currently studying the role of AIF in in 
vivo cardiac transplantation models using endothelium-specific AIF knockout mice generated 
by Cre-LoxP recombinase system. We plan on investigating the role of AIF in inducing 
necroptosis in other cell types such as renal tubular epithelial cells and believe that evaluating 
cellular function following IRI is as important as evaluating cellular survival. In addition to 
preserving cellular survival, it would be worthwhile investigating the role of the potential 
therapeutic strategies in maintaining cellular function as well. This is important because organ 
function is ultimately dependent on the integrated activities of its cells. Finally, we would like 
to investigate the most suitable delivery and administration methods of the identified 
pharmacological agents. 
4.10 – Limitations  
As with all in vitro experiments, a limitation of this study is that the in vitro cold 
hypoxia-reoxygenation injury model used may not accurately represent the in vivo and clinical 
conditions. For the in vitro cold hypoxia phase, anaerobic GENbags were used. The GENbags 
use a chemical generator sachet to induce hypoxia. Although the results of the in vitro cold 
hypoxia-reoxygenation injury were repeated with hypoxia induction in the Hypoxystation, the 
results may not reflect physiological hypoxia. The GENbags also generate heat in the first 30- 
60 minutes of the chemical reaction that induces hypoxia while the Hypoxystation can only be 
set as low as 10°C, which does not reflect clinical conditions involved in organ transplantation. 
In vitro experiments using a single cell-type, as is the case with this study, also do not take into 
account the complex physiological and pathological cellular responses triggered by the cell’s 
external environment. The cells may also react differently in in vivo and clinical settings 
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depending on their interaction with leukocytes. Furthermore, the pathways involved in one 
cell-type may not be activated/involved in other cell types. In this study, endothelial cells were 
used to study the effects of IRI in the context of organ transplantation. Endothelial cells 
represent only one component of IRI. They are also relatively resistant to hypoxia due to low-
energy turnover compared to cardiomyocytes (cardiac transplantation) or kidney tubular 
epithelial cells (renal transplantation). Finally, the concentration of the proinflammatory 
cytokines used in the in vitro settings may not be reflective of their physiological levels. In this 
study, these problems were addressed by repeating in vivo experiments involving a clinically 
relevant model cardiac transplantation.  
To study the various pathways involved in necroptosis, several drugs were used. The 
drugs used may have off-target effects and may influence other pathways involved. The use of 
the drugs studied in the in vitro as well as in vivo studies may not be clinically applicable and 
may have toxic effects at the concentrations used. This study did not address adverse effects 
related to drug concentrations. This is particularly true for Alisporivir, which was discontinued 
due to severe adverse effects (e.g., pancreatitis) following late stage clinical development as a 
combination therapy for the treatment of HCV infection [221, 222]. Both CsA and Alisporivir 
are cyclophilin-binding molecules and may bind non-specifically to other cyclophilins [104, 
147, 148, 211, 212]. This problem was addressed by using gene knock-out and siRNA 
interference silencing. However, these techniques may not be truly effective due to substantial 
genetic variability, and siRNA interference silencing is limited to a few days. These problems 
may be overcome by the use of shRNA interference silencing and CRIPSPR/Cas9 genome 
editing. 
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While data from this study indicate that AIF-silencing in endothelial cells confers 
protection against hypoxia/reoxygenation-induced necroptosis, AIF is a physiologically vital 
molecule essential in cellular bioenergetics, and its inhibition in cells with high-energy 
turnover such as cardiomyocytes (cardiac transplantation) or kidney tubular epithelial cells 
(renal transplantation) may exacerbate graft injury [147, 148]. A potential strategy may be to 
inhibit AIF translocation to the nucleus rather than its inhibition. A therapeutic strategy aimed 
at preventing AIF translocation globally in the context of organ transplantation is yet to be 
designed. 
4.11 – Conclusion and Study Significance  
In this study, we corroborated findings from our previous study and presented evidence 
indicating that targeting CypD-mediated mPTP formation presents a comprehensive 
therapeutic strategy in organ transplantation [104]. We showed the role of CypD-mediated 
mPTP formation in necroptosis using in vitro and in vivo experiments and investigated the 
putative mechanisms activated downstream of mPTP formation. Our findings established the 
role of AIF in necroptosis in endothelial cells and indicated that targeting AIF translocation 
yields even greater protection than targeting CypD-mediated mPTP formation in organ 
transplantation.  
It is important to note that while the role of IRI-induced necroptosis in organ 
transplantation is well-established, the development of clinically applicable pharmacological 
agents in disrupting it represents a significant obstacle [102, 104, 202, 203, 206]. The ‘ideal’ 
pharmacological inhibitor will disrupt necroptosis without perturbing the vital pro-survival 
physiological functions of the mediators involved. The goal of this study was to identify and 
develop a better understanding of the downstream mechanisms of IRI-induced necroptosis. We 
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believe that this will enable the generation of therapeutic strategies aimed at mitigating IRI and 
the subsequent inflammatory and alloimmune responses, ultimately promoting graft survival 
and function. Furthermore, the use of these pharmacological agents during donor organ storage 
will enhance the functional preservation of organs and enable the use of marginal donors, 
thereby addressing donor organ shortage.  
101 
 
REFERENCES 
1. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 
2016;13(6):368–378. doi:10.1038/nrcardio.2016.25. 
 
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 
sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global 
Burden of Disease Study 2010 [published correction appears in Lancet. 2013 Feb 
23;381(9867):628. AlMazroa, Mohammad A [added]; Memish, Ziad A [added]]. Lancet. 
2012;380(9859):2163–2196. doi:10.1016/S0140-6736(12)61729-2. 
 
3. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat 
Rev Cardiol. 2011;8(1):30–41. doi:10.1038/nrcardio.2010.165. 
 
4. Angela Felicia Sunjaya and Anthony Paulo Sunjaya. Combating Donor Organ Shortage: 
Organ Care System Prolonging Organ Storage Time and Improving the Outcome of 
Heart Transplantations. Cardiovascular Therapeutics. Vol. 2019, Article ID 9482797, 7 
pages, 2019. https://doi.org/10.1155/2019/9482797. 
 
5. Wittwer T, Wahlers T. Marginal donor grafts in heart transplantation: lessons learned 
from 25 years of experience. Transpl Int. 2008;21:113-25. 10.1111/j.1432-
2277.2007.00603.x. 
 
6. Harris C, Cao C, Croce B, Munkholm-Larsen S. Heart transplantation. Ann Cardiothorac 
Surg. 2018;7(1):172. doi:10.21037/acs.2018.01.11. 
 
7. Kittleson MM, Kobashigawa JA. Cardiac transplantation: current outcomes and 
contemporary controversies. JACC Heart Fail. 2017;5:857–868. doi: 
10.1016/j.jchf.2017.08.021. 
 
8. Kim IC, Youn JC, Kobashigawa JA. The Past, Present and Future of Heart 
Transplantation. Korean Circ J. 2018;48(7):565–590. doi:10.4070/kcj.2018.0189. 
 
9. Lund LH, Edwards LB, Dipchand AI., et al; International Society for Heart and Lung 
Transplantation. The Registry of the International Society for Heart and Lung 
Transplantation: thirty-third adult heart transplantation report-2016; focus theme: primary 
diagnostic indications for transplant. J Heart Lung Transplant. 2016. 
October;35(10):1158-1169. doi: 10.1016/j.healun.2016.08.017. 
 
10. Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC. Heart transplantation: 
challenges facing the field. Cold Spring Harb Perspect Med. 
2014;4(5):10.1101/cshperspect.a015636 a015636. Published 2014 May 1. 
doi:10.1101/cshperspect.a015636. 
102 
 
 
11. Potena, L., Zuckermann, A., Barberini, F. et al. Complications of Cardiac 
Transplantation. Curr Cardiol Rep 20, 73 (2018). https://doi-
org.proxy1.lib.uwo.ca/10.1007/s11886-018-1018-3. 
 
12. Khush KK, Menza R, Nguyen J, Zaroff JG, Goldstein BA. Donor predictors of allograft 
use and recipient outcomes after heart transplantation. Circ Heart Fail. 2013;6(2):300–
309. doi:10.1161/CIRCHEARTFAILURE.112.000165. 
 
13. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion 
injury. Int Rev Cell Mol Biol. 2012;298:229–317. doi:10.1016/B978-0-12-394309-
5.00006-7. 
 
14. Sanada S., Komuro I., Kitakaze M. Pathophysiology of myocardial reperfusion injury: 
preconditioning, postconditioning, and translational aspects of protective 
measures. American Journal of Physiology. Heart and Circulatory 
Physiology. 2011;301(5):H1723–H1741. doi: 10.1152/ajpheart.00553.2011. 
 
15. Holger K. Eltzschig, Charles D. Collard, Vascular ischaemia and reperfusion 
injury, British Medical Bulletin, Volume 70, Issue 1, 2004, Pages 71–
86, https://doi.org/10.1093/bmb/ldh025.  
 
16. Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondria in 
ischemia/reperfusion injury. J. Biol. Chem. 2002;277:29181–29186. 
 
17. Wu MY, Yiang GT, Liao WT, et al. Current mechanistic concepts in ischemia and 
reperfusion injury. Cell Physiol Biochem. 2018;46:1650–1667. doi:10.1159/000489241. 
 
18. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J 
Pathol. 2000;190:255–266. 
 
19. Granger DN, Korthuis RJ. Physiologic mechanisms of postischemic tissue injury. Annu 
Rev Physiol 1995; 57: 311–332. 
 
20. Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion 
injury. Basic Res Cardiol. 2009;104(2):181–188. doi:10.1007/s00395-009-0004-8. 
 
21. Slegtenhorst BR, Dor FJ, Rodriguez H, Voskuil FJ, Tullius SG. Ischemia/reperfusion 
Injury and its Consequences on Immunity and Inflammation. Curr Transplant Rep. 
2014;1(3):147–154. doi:10.1007/s40472-014-0017-6. 
 
22. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, et al. The 
beneficial effect of human recombinant superoxide dismutase on acute and chronic 
103 
 
rejection events in recipients of cadaveric renal transplants. Transplantation. 1994 
Jan;57(2):211–217. 
 
23. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 
1994;12:991–1045. 
 
24. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: An integrated 
view. Immunol Rev. 2011 Sep;243(1):136–151. 
 
25. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple 
signalling pathways on ROS production? Nat Rev Immunol. 2010 Mar;10(3):210–215. 
 
26. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev 
Immunol. 2010 Dec;10(12):826–837. 
 
27. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost. 2007 
May;97(5):738–747. 
 
28. Nathan C. Neutrophils and immunity: Challenges and opportunities. Nat Rev 
Immunol. 2006 Mar;6(3):173–182. 
 
29. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, et al. Distinct macrophage 
phenotypes contribute to kidney injury and repair. J Am Soc Nephrol. 2011 
Feb;22(2):317–326. 
 
30. Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils—a key 
component of ischemia-reperfusion injury. Shock. 2013;40(6):463–70. Epub 2013/10/04. 
10.1097/SHK.0000000000000044. 
 
31. Gordon S, Martinez FO. Alternative activation of macrophages: Mechanism and 
functions. Immunity. 2010 May 28;32(5):593–604. 
 
32. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive 
component of innate immunity. Adv Immunol. 2013;120:163–184. 
 
33. Schlaepfer E, Rochat MA, Duo L, Speck RF. Triggering TLR2, -3, -4, -5, and -8 
reinforces the restrictive nature of M1- and M2-polarized macrophages to HIV. J Virol. 
2014;88(17):9769–9781. doi:10.1128/JVI.01053-14. 
 
34. Quero L, Hanser E, Manigold T, Tiaden AN, Kyburz D. TLR2 stimulation impairs anti-
inflammatory activity of M2-like macrophages, generating a chimeric M1/M2 
phenotype. Arthritis Res Ther. (2017) 19:245. 10.1186/s13075-017-1447-1. 
 
104 
 
35. Atri C, Guerfali FZ, Laouini D. Role of Human Macrophage Polarization in 
Inflammation during Infectious Diseases. Int J Mol Sci. 2018;19(6):1801. Published 2018 
Jun 19. doi:10.3390/ijms19061801. 
 
36. Beyer M., Mallmann M.R., Xue J., Staratschek-Jox A., Vorholt D., Krebs W., Sommer 
D., Sander J., Mertens C., Nino-Castro A., et al. High-resolution transcriptome of human 
macrophages. PLoS ONE. 2012;7:e45466. doi: 10.1371/journal.pone.0045466. 
 
37. Vogel D.Y., Glim J.E., Stavenuiter A.W., Breur M., Heijnen P., Amor S., Dijkstra C.D., 
Beelen R.H. Human macrophage polarization in vitro: Maturation and activation methods 
compared. Immunobiology. 2014;219:695–703. doi: 10.1016/j.imbio.2014.05.002. 
 
38. Italiani P., Mazza E.M., Lucchesi D., Cifola I., Gemelli C., Grande A., Battaglia C., 
Bicciato S., Boraschi D. Transcriptomic profiling of the development of the inflammatory 
response in human monocytes in vitro. PLoS ONE. 2014;9:e87680. doi: 
10.1371/journal.pone.0087680. 
 
39. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the 
human monocyte-to-macrophage differentiation and polarization: New molecules and 
patterns of gene expression. J. Immunol. 2006;177:7303–7311. doi: 
10.4049/jimmunol.177.10.7303. 
 
40. Zhang Z-X, Huang X, Jiang J, Lau A, Yin Z, Liu W, et al. . Natural killer cells mediate 
long-term kidney allograft injury. Transplantation. (2015) 99:916–24. 
10.1097/TP.0000000000000665. 
 
41. Benichou G, Yamada Y, Aoyama A, Madsen JC. Natural killer cells in rejection and 
tolerance of solid organ allografts. Curr Opin Organ Transplant. 2011;16(1):47–53. 
doi:10.1097/MOT.0b013e32834254cf. 
 
42. Al-Lamki RS, Bradley JR, Pober JS. Endothelial cells in allograft rejection. 
Transplantation. 2008;86(10):1340–1348. doi:10.1097/TP.0b013e3181891d8b. 
 
43. Pratschke J, Stauch D, Kotsch K. Role of NK and NKT cells in solid organ 
transplantation. Transpl Int. 2009;22:859–868. doi: 10.1111/j.1432-2277.2009.00884.x. 
 
44. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, Madsen JC. The changing 
role of natural killer cells in solid organ rejection and tolerance. Transplantation. 
2006;81:811–817. doi: 10.1097/01.tp.0000202844.33794.0e. 
 
45. Langer HF, Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol 
Med. 2009;13(7):1211–1220. doi:10.1111/j.1582-4934.2009.00811.x. 
 
105 
 
46. Liao JK. Linking endothelial dysfunction with endothelial cell activation. J Clin Invest. 
2013;123(2):540–541. doi:10.1172/JCI66843. 
 
47. Tuuminen R, Syrjala S, Krebs R, Keranen MA, Koli K, Abo-Ramadan U, et al. Donor 
simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and 
chronic rejection through microvascular protection. Circulation. 2011 Sep 
6;124(10):1138–1150. 
 
48. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002 Feb 5;105(5):656–
662. 
 
49. Yang Q, He GW, Underwood MJ, Yu CM. Cellular and molecular mechanisms of 
endothelial ischemia/reperfusion injury: perspectives and implications for postischemic 
myocardial protection. Am J Transl Res. 2016;8(2):765–777. Published 2016 Feb 15. 
 
50. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of 
oxidant stress. Circ Res. 2000;87:840–844. 
 
51. Hirase T., Node K. Endothelial dysfunction as a cellular mechanism for vascular 
failure. Am. J. Physiol. Circ. Physiol. 2012;302:H499–H505. doi: 
10.1152/ajpheart.00325.2011. 
 
52. Devan AE, Umpierre D, Harrison ML, et al. Endothelial ischemia-reperfusion injury in 
humans: association with age and habitual exercise. Am J Physiol Heart Circ Physiol. 
2011;300(3):H813–H819. doi:10.1152/ajpheart.00845.2010. 
 
53. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced 
endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion 
molecules and proinflammatory cytokines. J Clin Invest. 1995;96(1):60–68. 
doi:10.1172/JCI118074. 
 
54. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The role of 
nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10:4–18. 
 
55. Jin RC, Loscalzo J. Vascular Nitric Oxide: Formation and Function. J Blood Med. 
2010;2010(1):147–162. doi:10.2147/JBM.S7000. 
 
56. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, 
tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial 
nitric-oxide synthase. J Biol Chem. 2003;278:22546–22554. 
 
57. Vinson AJ, Rose C, Kiberd BA, et al. Factors Associated With Prolonged Warm 
Ischemia Time Among Deceased Donor Kidney Transplant Recipients. Transplant 
Direct. 2018;4(5):e342. Published 2018 Apr 18. doi:10.1097/TXD.0000000000000781. 
106 
 
 
58. Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA, Bonser RS. The importance 
of cold and warm cardiac ischemia for survival after heart transplantation. 
Transplantation. 2008;86(4):542–547. 
 
59. Singh SSA, Dalzell JR, Berry C, Al-Attar N. Primary graft dysfunction after heart 
transplantation: a thorn amongst the roses. Heart Fail Rev. 2019;24(5):805–820. 
doi:10.1007/s10741-019-09794-1. 
 
60. Kobashigawa J, Zuckermann A, Macdonald P., et al; Consensus Conference participants. 
Report from a consensus conference on primary graft dysfunction after cardiac 
transplantation. J Heart Lung Transplant. 2014. April;33(4):327‐340. 
doi: 10.1016/j.healun.2014.02.027. 
 
61. George TJ, Arnaoutakis GJ, Beaty CA, Shah AS, Conte JV, Halushka MK. A novel 
method of measuring cardiac preservation injury demonstrates University of Wisconsin 
solution is associated with less ischemic necrosis than Celsior in early cardiac allograft 
biopsy specimens. J Heart Lung Transplant. 2012;31(4):410–418. 
doi:10.1016/j.healun.2011.11.023. 
 
62. Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon. 
2011;9:160-7. 10.1016/j.surge.2010.11.023. 
 
63. Weil R 3rd, Clarke DR, Iwaki Y, et al. Hyperacute rejection of a transplanted human 
heart. Transplantation. 1981;32(1):71–72. 
 
64. Kaczorowski DJ, Datta J, Kamoun M, Dries DL, Woo YJ. Profound hyperacute cardiac 
allograft rejection rescue with biventricular mechanical circulatory support and 
plasmapheresis, intravenous immunoglobulin, and rituximab therapy. J Cardiothorac 
Surg. 2013;8:48. Published 2013 Mar 16. doi:10.1186/1749-8090-8-48. 
 
65. Kittleson MM, Patel JK, Kobashigawa JA. Chapter 72: cardiac transplantation. In: Fuster 
V, Harrington RA, Narula J, Eapen ZJ, editors. Hurst's the Heart. 14th ed. New York 
(NY): McGraw-Hill; 2017. 
 
66. Kobashigawa J. Clinical Guide to Heart Transplantation. Los Angeles (CA): Springer. 
2017. 
 
67. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung 
Transplantation guidelines for the care of heart transplant recipients. J Heart Lung 
Transplant. 2010;29:914–956. 
 
68. Labarrere CA, Jaeger BR. Biomarkers of heart transplant rejection: the good, the bad, and 
the ugly! Transl Res. 2012;159:238–251. 
107 
 
 
69. Musick A, Kim A, Glass C. Acute cellular rejection. PathologyOutlines.com website. 
http://www.pathologyoutlines.com/topic/heartacutecellularrejection.html. Accessed 
March 4th, 2020. 
 
70. Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr Nephrol. 
2010;25(1):61–74. doi:10.1007/s00467-008-1020-x 
 
71. Tan CD, Baldwin WM, Rodriguez ER. Update on cardiac transplantation 
pathology. Arch Pathol Lab Med. 2007;131:1169–91. 10.1043/1543-
2165(2007)131[1169:UOCTP]2.0.CO;2. 
 
72. Auchincloss H, Sultan H. Antigen processing and presentation in transplantation. Curr 
Opin Immunol. (1996) 8:681–7.10.1016/S0952-7915(96)80086-0. 
 
73. Azzawi M, Hasleton PS, Hutchinson IV. TNF-alpha in acute cardiac transplant 
rejection. Cytokines Cell Mol Ther. 1999;5:41–49. 
 
74. Hummel M, Kurian SM, Lin S, et al. Intragraft TNF receptor signaling contributes to 
activation of innate and adaptive immunity in a renal allograft 
model. Transplantation. 2009;87(2):178–188. 
 
75. Zhang T, Pierson RN 3rd, Azimzadeh AM. Update on CD40 and CD154 blockade in 
transplant models. Immunotherapy. 2015;7(8):899–911. doi:10.2217/IMT.15.54. 
 
76. Weigt SS, Palchevskiy V, Belperio JA. Inflammasomes and IL-1 biology in the 
pathogenesis of allograft dysfunction. J Clin Invest. 2017;127(6):2022–2029. 
doi:10.1172/JCI93537. 
 
77. Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac 
transplantation: emerging knowledge in diagnosis and management: a scientific statement 
from the American Heart Association. Circulation. 2015;131:1608–1639. 
 
78. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and 
Lung Transplantation Working Formulation for the standardization of nomenclature in 
the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart 
Lung Transplant. 2013;32:1147–1162. 
 
79. Chih S, Chruscinski A, Ross HJ, Tinckam K, Butany J, Rao V. Antibody-mediated 
rejection: an evolving entity in heart transplantation. J Transplant. 2012;2012:210210. 
doi:10.1155/2012/210210. 
 
108 
 
80. Murata K, Baldwin WM., III Mechanisms of complement activation, C4d deposition, and 
their contribution to the pathogenesis of antibody-mediated rejection. Transplantation 
Reviews. 2009;23(3):139–150. 
 
81. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed 
antibodies after heart transplantation is associated with poor allograft 
outcome. Transplantation. 2005;80:1019–1025. 
 
82. Coutance G, Ouldamar S, Rouvier P, et al. Late antibody-mediated rejection after heart 
transplantation: mortality, graft function, and fulminant cardiac allograft vasculopathy. J 
Heart Lung Transplant. 2015;34:1050–1057. 
 
83. Skorić B, Čikeš M, Ljubas Maček J, et al. Cardiac allograft vasculopathy: diagnosis, 
therapy, and prognosis. Croat Med J. 2014;55(6):562–576. doi:10.3325/cmj.2014.55.562. 
 
84. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. 
The Registry of the International Society for Heart and Lung Transplantation: thirtieth 
official adult heart transplant report – 2013; focus theme: age. J Heart Lung 
Transplant. 2013;32:951–64. doi: 10.1016/j.healun.2013.08.006. 
 
85. Ramzy D, Rao V, Brahm J, Miriuka S, Delgado D, Ross HJ. Cardiac allograft 
vasculopathy: a review. Can J Surg. 2005;48(4):319–327. 
 
86. Hiemann NE, Wellnhofer E, Knosalla C, Lehmkuhl HB, Stein J, Hetzer R, Meyer R. 
Prognostic impact of microvasculopathy on survival after heart transplantation: evidence 
from 9713 endomyocardial biopsies. Circulation. 2007;116(11):1274–1282. 
 
87. Musick A, Glass C. Chronic allograft vasculopathy. PathologyOutlines.com website. 
https://www.pathologyoutlines.com/topic/heartchronicgraftvasculopathy.html. Accessed 
March 4th, 2020. 
 
88. Weis M, von Scheidt W. Cardiac allograft vasculopathy: A 
review. Circulation. 1997;96:2069–2077. doi: 10.1161/01.CIR.96.6.2069. 
 
89. Vassalli G, Gallino A, Weis M, von Scheidt W, Kappenberger L, von Segesser LK, et 
al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur 
Heart J. 2003;24(13):1180–8. Epub 2003/07/02. 10.1016/s0195-668x(03)00237-9. 
 
90. Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Is intravenous glucocorticoid 
therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized 
trial. J Am Coll Cardiol. 1993;21:1142–1144. 
 
91. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 
2008. Apr 22;117(16):2131-2141. doi: 10.1161/CIRCULATIONAHA.107.711911. 
109 
 
 
92. Jennings Douglas L., Lange Nicholas, Shullo Michael, Latif Farhana, Restaino Susan, 
Topkara Veli K., Takeda Koji, Takayama Hiroo, Naka Yoshifumi, Farr Maryjane, 
Colombo Paolo, Baker William L. Outcomes associated with mammalian target of 
rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-
analysis. International Journal of Cardiology. 2018;265:71–76. 
 
93. Stoica SC, Goddard M, Large SR. The endothelium in clinical cardiac 
transplantation. Ann Thorac Surg. 2002;73:1002–1008. 
 
94. Rifle G, Mousson C, Hervé P. Endothelial cells in organ transplantation: Friends or 
foes? Transplantation. 2006;82:S4–S5. 
 
95. Singhal AK, Symons JD, Boudina S, Jaishy B, Shiu YT. Role of Endothelial Cells in 
Myocardial Ischemia-Reperfusion Injury. Vasc Dis Prev. 2010;7:1–14. 
doi:10.2174/1874120701007010001. 
 
96. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the nitric oxide 
synthase pathway. Arterioscler Thromb. 2003;23:567–75. 
 
97. Seino K, Azuma M, Bashuda H, Fukao K, Yagita H, Okumura K. CD86 (B70/B7-2) on 
endothelial cells co-stimulates allogeneic CD4+ T cells. Int Immunol (1995) 7(8):1331–
7.10.1093/intimm/7.8.1331. 
 
98. Jollow KC, Zimring JC, Sundstrom JB, Ansari AA. CD40 ligation induced phenotypic 
and functional expression of CD80 by human cardiac microvascular endothelial 
cells. Transplantation (1999) 68(3):430–9.10.1097/00007890-199908150-00016. 
 
99. Tan PH, Chan C, Xue SA, Dong R, Ananthesayanan B, Manunta M, et al. Phenotypic 
and functional differences between human saphenous vein (HSVEC) and umbilical vein 
(HUVEC) endothelial cells. Atherosclerosis (2004) 173(2):171–
83.10.1016/j.atherosclerosis.2003.12.011. 
 
100. Pober JS, Merola J, Liu R, Manes TD. Antigen Presentation by Vascular Cells. Front 
Immunol. 2017;8:1907. Published 2017 Dec 22. doi:10.3389/fimmu.2017.01907. 
 
101. Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death 
Differ. 2018;25(3):486–541. doi:10.1038/s41418-017-0012-4. 
 
102. Linkermann A., Hackl M.J., Kunzendorf U., Walczak H., Krautwald S., Jevnikar 
A.M. Necroptosis in immunity and ischemia-reperfusion injury. Am. J. 
Transpl. 2013;13:2797–2804. doi: 10.1111/ajt.12448. 
 
110 
 
103. Lau A, et al. RIPK3-mediated necroptosis promotes donor kidney inflammatory 
injury and reduces allograft survival. Am J Transplant. 2013;13(11):2805–2818. doi: 
10.1111/ajt.12447. 
 
104. Gan, I, Jiang, J, Lian, D, et al. Mitochondrial permeability regulates cardiac 
endothelial cell necroptosis and cardiac allograft rejection. Am J 
Transplant. 2019; 19: 686– 698. https://doi.org/10.1111/ajt.15112. 
 
105. Choi ME, Price DR, Ryter SW, Choi AMK. Necroptosis: a crucial pathogenic 
mediator of human disease. JCI Insight. 2019;4(15):e128834. Published 2019 Aug 8. 
doi:10.1172/jci.insight.128834. 
 
106. Marshall KD, Baines CP. Necroptosis: is there a role for mitochondria?. Front 
Physiol. 2014;5:323. Published 2014 Aug 26. doi:10.3389/fphys.2014.00323. 
 
107. Tsuchiya Y, Nakabayashi O, Nakano H. FLIP the Switch: Regulation of Apoptosis 
and Necroptosis by cFLIP. Int J Mol Sci. 2015;16(12):30321–30341. Published 2015 Dec 
18. doi:10.3390/ijms161226232. 
 
108. Safa AR. Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy. J Carcinog 
Mutagen. 2013;Suppl 6:003. doi:10.4172/2157-2518.S6-003. 
 
109. Dhuriya YK, Sharma D. Necroptosis: a regulated inflammatory mode of cell death. J 
Neuroinflammation. 2018;15(1):199. Published 2018 Jul 6. doi:10.1186/s12974-018-
1235-0. 
 
110. Cho YS. The role of necroptosis in the treatment of diseases. BMB Rep. 
2018;51(5):219–224. doi:10.5483/bmbrep.2018.51.5.074. 
 
111. Wang C, Youle RJ. The role of mitochondria in apoptosis*. Annu Rev Genet. 
2009;43:95–118. doi:10.1146/annurev-genet-102108-134850. 
 
112. Parsons M.J., Green D.R. Mitochondria in cell death. Essays Biochem. 2010;47:99–
114. doi: 10.1042/bse0470099. 
 
113. Tait SW, Green DR. Mitochondrial regulation of cell death. Cold Spring Harb 
Perspect Biol. 2013;5(9):a008706. Published 2013 Sep 1. 
doi:10.1101/cshperspect.a008706. 
 
114. Singh R., Letai A., Sarosiek K. Regulation of apoptosis in health and disease: the 
balancing act of BCL-2 family proteins. Nature Reviews Molecular Cell 
Biology. 2019;20(3):175–193. doi: 10.1038/s41580-018-0089-8. 
 
111 
 
115. Lin Y., Choksi S., Shen H. M., Yang Q. F., Hur G. M., Kim Y. S., et al. 
(2004). Tumor necrosis factor-induced nonapoptotic cell death requires receptor-
interacting protein-mediated cellular reactive oxygen species accumulation. J. Biol. 
Chem. 279, 10822–10828 10.1074/jbc.M313141200. 
 
116. Vanlangenakker N., Vanden Berghe T., Bogaert P., Laukens B., Zobel K., Deshayes 
K., et al. (2011). cIAP1 and TAK1 protect cells from TNF-induced necrosis by 
preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death 
Differ. 18, 656–665 10.1038/cdd.2010.138. 
 
117. Ardestani S., Deskins D. L., Young P. P. (2013). Membrane TNF-alpha-activated 
programmed necrosis is mediated by Ceramide-induced reactive oxygen species. J. Mol. 
Signal. 8, 12 10.1186/1750-2187-8-12. 
 
118. Schulze-Osthoff K., Bakker A. C., Vanhaesebroeck B., Beyaert R., Jacob W. A., 
Fiers W. (1992). Cytotoxic activity of tumor necrosis factor is mediated by early damage 
of mitochondrial functions. Evidence for the involvement of mitochondrial radical 
generation. J. Biol. Chem. 267, 5317–5323. 
 
119. Goossens V., Stangé G., Moens K., Pipeleers D., Grooten J. (1999). Regulation of 
tumor necrosis factor-induced, mitochondria- and reactive oxygen species-dependent cell 
death by the electron flux through the electron transport chain complex I. Antioxid. Redox 
Signal. 1, 285–295. 
 
120. Temkin V., Huang Q., Liu H., Osada H., Pope R. M. (2006). Inhibition of ADP/ATP 
exchange in receptor-interacting protein-mediated necrosis. Mol. Cell. Biol. 26, 2215–
2225 10.1128/MCB.26.6.2215-2225.2006. 
 
121. Zhang D. W., Shao J., Lin J., Zhang N., Lu B. J., Lin S. C., et al. (2009). RIP3, an 
energy metabolism regulator that switches TNF-induced cell death from apoptosis to 
necrosis. Science 325, 332–336 10.1126/science.1172308. 
 
122. Davis C. W., Hawkins B. J., Ramasamy S., Irrinki K. M., Cameron B. A., Islam K., et 
al. (2010). Nitration of the mitochondrial complex I subunit NDUFB8 elicits RIP1- and 
RIP3-mediated necrosis. Free Radic. Biol. Med. 48, 306–317 
10.1016/j.freeradbiomed.2009.11.001. 
 
123. Wang Z., Jiang H., Chen S., Du F., Wang X. (2012). The mitochondrial phosphatase 
PGAM5 functions at the convergence point of multiple necrotic death 
pathways. Cell 148, 228–243 10.1016/j.cell.2011.11.030. 
 
124. Zhang L., Jiang F., Chen Y., Luo J., Liu S., Zhang B., et al. (2013). Necrostatin-1 
attenuates ischemia injury induced cell death in rat tubular cell line NRK-52E through 
decreased Drp1 expression. Int. J. Mol. Sci. 14, 24742–24754 10.3390/ijms141224742. 
112 
 
 
125. Baines C. P., Kaiser R. A., Purcell N. H., Blair N. S., Osinska H., Hambleton M. A., 
et al. (2005). Loss of cyclophilin D reveals a critical role for mitochondrial permeability 
transition in cell death. Nature 434, 658–662 10.1038/nature03434. 
 
126. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., et al. 
(2005). Cyclophilin D-dependent mitochondrial permeability transition regulates some 
necrotic but not apoptotic cell death. Nature 434, 652–658 10.1038/nature03317. 
 
127. Schinzel A. C., Takeuchi O., Huang Z., Fisher J. K., Zhou Z., Rubens J., et al. 
(2005). Cyclophilin D is a component of mitochondrial permeability transition and 
mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. 
Sci.U.S.A. 102, 12005–12010 10.1073/pnas.0505294102. 
 
128. Tait S. W., Oberst A., Quarato G., Milasta S., Haller M., Wang R., et al. 
(2013). Widespread mitochondrial depletion via mitophagy does not compromise 
necroptosis. Cell Rep. 5, 878–885 10.1016/j.celrep.2013.10.034. 
 
129. Murphy J. M., Czabotar P. E., Hildebrand J. M., Lucet I. S., Zhang J. G., Alvarez-
Diaz S., et al. (2013). The pseudokinase MLKL mediates necroptosis via a molecular 
switch mechanism. Immunity 39, 443–453 10.1016/j.immuni.2013.06.018. 
 
130. Remijsen Q., Goossens V., Grootjans S., Van den Haute C., Vanlangenakker N., 
Dondelinger Y., et al. (2014). Depletion of RIPK3 or MLKL blocks TNF-driven 
necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis. Cell 
Death Dis. 5, e1004 10.1038/cddis.2013.531. 
 
131. Moujalled D. M., Cook W. D., Murphy J. M., Vaux D. L. (2014). Necroptosis 
induced by RIPK3 requires MLKL but not Drp1. Cell Death Dis. 5, e1086 
10.1038/cddis.2014.18. 
 
132. Linkermann A., Bräsen J. H., Darding M., Jin M. K., Sanz A. B., Heller J. O., et al. 
(2013). Two independent pathways of regulated necrosis mediate ischemia-reperfusion 
injury. Proc. Natl. Acad. Sci. U.S.A. 110, 12024–12029 10.1073/pnas.1305538110.  
 
133. Cai Z., Jitkaew S., Zhao J., Chiang H. C., Choksi S., Liu J., et al. (2014). Plasma 
membrane translocation of trimerized MLKL protein is required for TNF-induced 
necroptosis. Nat. Cell Biol. 16, 55–65 10.1038/ncb2883. 
 
134. Chen X., Li W., Ren J., Huang D., He W. T., Song Y., et al. (2014). Translocation of 
mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell 
death. Cell Res. 24, 105–121 10.1038/cr.2013.171. 
 
113 
 
135. Dondelinger Y., Declercq W., Montessuit S., Roelandt R., Goncalves A., Bruggeman 
I., et al. (2014). MLKL compromises plasma membrane integrity by binding to 
phosphatidylinositol phosphates. Cell Rep. 7, 971–981 10.1016/j.celrep.2014.04.026. 
 
136. Wang H., Sun L., Su L., Rizo J., Liu L., Wang L. F., et al. (2014). Mixed lineage 
kinase domain-like protein MLKL causes necrotic membrane disruption upon 
phosphorylation by RIP3. Mol. Cell 54, 133–146 10.1016/j.molcel.2014.03.003. 
 
137. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell 
Cardiol. 2009;46:821–31. 
 
138. Karch J, Molkentin JD. Identifying the components of the elusive mitochondrial 
permeability transition pore. Proc Natl Acad Sci U S A. 2014;111(29):10396–10397. 
doi:10.1073/pnas.1410104111. 
 
139. Morciano G., Bonora M., Campo G., Aquila G., Rizzo P., Giorgi C., et al. 
(2017). Mechanistic role of mPTP in ischemia-reperfusion injury. Adv. Exp. Med. 
Biol. 982 169–189. 10.1007/978-3-319-55330-6-9. 
 
140. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability 
transition pore opening at reperfusion protects against ischaemia-reperfusion 
injury. Cardiovasc Res. 2003;60(3):617–625. doi:10.1016/j.cardiores.2003.09.025. 
 
141. Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial 
permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol 
Cell Cardiol. 2015;78:23–34. 
 
142. Karch J, et al. Bax and Bak function as the outer membrane component of the 
mitochondrial permeability pore in regulating necrotic cell death in 
mice. eLife. 2013;2:e00772. 
 
143. Karch J, Kanisicak O, Brody MJ, Sargent MA, Michael DM, Molkentin JD. 
Necroptosis Interfaces with MOMP and the MPTP in Mediating Cell Death. PLoS One. 
2015;10(6):e0130520. Published 2015 Jun 10. doi:10.1371/journal.pone.0130520. 
 
144. Wong R, Steenbergen C, Murphy E. Mitochondrial permeability transition pore and 
calcium handling. Methods Mol Biol. 2012;810:235–242. doi:10.1007/978-1-61779-382-
0_15. 
 
145. Benítez-Guzmán A, Arriaga-Pizano L, Morán J, Gutiérrez-Pabello JA. Endonuclease 
G takes part in AIF-mediated caspase-independent apoptosis in Mycobacterium bovis-
infected bovine macrophages. Vet Res. 2018;49(1):69. Published 2018 Jul 18. 
doi:10.1186/s13567-018-0567-1. 
 
114 
 
146. Marzetti E, Wohlgemuth SE, Lees HA, et al. Age-related activation of mitochondrial 
caspase-independent apoptotic signaling in rat gastrocnemius muscle. Mechanisms of 
Ageing and Development. 2008 Sep;129(9):542-549. DOI: 10.1016/j.mad.2008.05.005. 
 
147. Bano D, Prehn JHM. Apoptosis-Inducing Factor (AIF) in Physiology and Disease: 
The Tale of a Repented Natural Born Killer. EBioMedicine. 2018;30:29–37. 
doi:10.1016/j.ebiom.2018.03.016. 
 
148. Sevrioukova IF. Apoptosis-inducing factor: structure, function, and redox 
regulation. Antioxid Redox Signal. 2011;14(12):2545–2579. doi:10.1089/ars.2010.3445. 
 
149. Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked 
mechanisms and therapeutic opportunities. Br J Pharmacol. 2014;171(8):2000–2016. 
doi:10.1111/bph.12416. 
 
150. Klein JA, et al. The harlequin mouse mutation downregulates apoptosis-inducing 
factor. Nature. 2002;419:367–374. doi: 10.1038/nature01034. 
 
151. Zhang W, Li D, Mehta JL. Role of AIF in human coronary artery endothelial cell 
apoptosis. American Journal of Physiology: Heart and Circulatory 
Physiology. 2004;286(1):H354–H358. 
 
152. Zhu C, Wang X, Deinum J, et al. Cyclophilin A participates in the nuclear 
translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J 
Exp Med. 2007;204(8):1741–1748. doi:10.1084/jem.20070193. 
 
153. Doti, N., Reuther, C., Scognamiglio, P. et al. Inhibition of the AIF/CypA complex 
protects against intrinsic death pathways induced by oxidative stress. Cell Death 
Dis 5, e993 (2014) doi:10.1038/cddis.2013.518.  
 
154. Zhao H, Jaffer T, Eguchi S, Wang Z, Linkermann A, Ma D. Role of necroptosis in the 
pathogenesis of solid organ injury. Cell Death Dis. 2015;6(11):e1975. Published 2015 
Nov 19. doi:10.1038/cddis.2015.316. 
 
155. Han J, Zhong CQ, Zhang DW. Programmed necrosis: Backup to and competitor with 
apoptosis in the immune system. Nat Immunol. 2011; 12: 1143–1149. 
 
156. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: The release of damage‐
associated molecular patterns and its physiological relevance. Immunity. 2013; 38: 209–
223. 
 
157. Linkermann A, Green DR. Necroptosis. N Engl J Med. 2014;370(5):455–465. 
doi:10.1056/NEJMra1310050. 
 
115 
 
158. Mannon RB. Necroptosis in solid organ transplantation: a missing link to immune 
activation. Am J Transplant. 2013;13:2785–2786. 
 
159. He S., Wang L., Miao L., Wang T., Du F., Zhao L., et al. (2009). Receptor interacting 
protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100–
1111 10.1016/j.cell.2009.05.021. 
 
160. Culic O., Gruwel M. L., Schrader J. (1997). Energy turnover of vascular endothelial 
cells. Am. J. Physiol. Physiol. 273 C205–C213. 10.1152/ajpcell.1997.273.1.C205.  
 
161. Quintero M, Colombo SL, Godfrey A, Moncada S. Mitochondria as signaling 
organelles in the vascular endothelium. Proc Natl Acad Sci U S A. 2006;103(14):5379–
5384. doi:10.1073/pnas.0601026103.  
 
162. Davidson S. M., Duchen M. R. Endothelial mitochondria: contributing to vascular 
function and disease. Circulation Research. 2007;100(8):1128–1141. doi: 
10.1161/01.RES.0000261970.18328.1d. 
 
163. Zhang H, Wang P, Bisetto S, et al. A novel fission-independent role of dynamin-
related protein 1 in cardiac mitochondrial respiration. Cardiovasc Res. 2017;113(2):160–
170. doi:10.1093/cvr/cvw212. 
 
164. Roca F. J., Ramakrishnan L. (2013). TNF dually mediates resistance and 
susceptibility to mycobacteria via mitochondrial reactive oxygen species. Cell 153, 521–
534 10.1016/j.cell.2013.03.022. 
 
165. Ch'en I. L., Tsau J. S., Molkentin J. D., Komatsu M., Hedrick S. M. 
(2011). Mechanisms of necroptosis in T cells. J. Exp. Med. 208, 633–641 
10.1084/jem.20110251.  
 
166. Murphy RC, Schneider E, Kinnally KW. Overexpression of Bcl-2 suppresses the 
calcium activation of a mitochondrial megachannel. FEBS Lett. 2001;497:73–76. 
 
167. Crompton M. On the involvement of mitochondrial intermembrane junctional 
complexes in apoptosis. Curr Med Chem. 2003;10:1473–84. 
 
168. Green DR, Kroemer G. The pathophysiology of mitochondrial cell 
death. Science. 2004;305:626–9. 
 
169. Hurst S, Hoek J, Sheu SS. Mitochondrial Ca2+ and regulation of the permeability 
transition pore. J Bioenerg Biomembr. 2017;49(1):27–47. doi:10.1007/s10863-016-9672-
x. 
 
116 
 
170. Tan Y, Wu C, De Veyra T, Greer PA. Ubiquitous calpains promote both apoptosis 
and survival signals in response to different cell death stimuli. J Biol 
Chem. (2006) 281:17689–98. 10.1074/jbc.M601978200.  
 
171. Gabellini C, Trisciuoglio D, Del Bufalo D. Non-canonical roles of Bcl-2 and Bcl-xL 
proteins: relevance of BH4 domain. Carcinogenesis. 2017;38(6):579–587. doi: 
10.1093/carcin/bgx016. 
 
172. Delavallée L, Cabon L, Galán-Malo P, Lorenzo HK, Susin SA. AIF-mediated 
caspase-independent necroptosis: a new chance for targeted therapeutics. IUBMB Life. 
2011;63: 221–232. 10.1002/iub.432. 
 
173. Chen Q, Szczepanek K, Hu Y, Thompson J, Lesnefsky EJ. A deficiency of apoptosis 
inducing factor (AIF) in Harlequin mouse heart mitochondria paradoxically reduces ROS 
generation during ischemia-reperfusion. Front Physiol. 2014;5:271. Published 2014 Jul 
22. doi:10.3389/fphys.2014.00271. 
 
174. Plesnila N., Zhu C., Culmsee C., Groger M., Moskowitz M.A., Blomgren K. Nuclear 
translocation of apoptosis-inducing factor after focal cerebral ischemia. J. Cereb. Blood 
Flow Metab. 2004;24:458–466. 
 
175. Kim G.T., Chun Y.S., Park J.W., Kim M.S. Role of apoptosis-inducing factor in 
myocardial cell death by ischemia-reperfusion. Biochem. Biophys. Res. 
Commun. 2003;309:619–624. 
 
176. Culmsee C, Zhu C, Landshamer S, et al. Apoptosis-inducing factor triggered by 
poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose 
deprivation and focal cerebral ischemia [published correction appears in J Neurosci. 2005 
Nov 16;25(46):table of contents. Pellechia, Maurizio [corrected to Pellecchia, 
Maurizio]]. J Neurosci. 2005;25(44):10262–10272. doi:10.1523/JNEUROSCI.2818-
05.2005. 
 
177. Lan S LF, Zhao G, Zhou T, Wu C, Kou J, Fan R, Qi X, Li Y, Jiang Y, Bai T, Li P, 
Liu L, Hao D, Zhang L, Li Y, Liu JY. Cyclosporine A increases hair follicle growth by 
suppressing apoptosis-inducing factor nuclear translocation: a new 
mechanism. Fundamental and Clinical Pharmacology. 2015;29:191–203. doi: 
10.1111/fcp.12100. 
 
178. Hu WL, Dong HY, Li Y, Ojcius DM, Li SJ, Yan J. Bid-Induced Release of 
AIF/EndoG from Mitochondria Causes Apoptosis of Macrophages during Infection 
with Leptospira interrogans. Front Cell Infect Microbiol. 2017;7:471. Published 2017 
Nov 14. doi:10.3389/fcimb.2017.00471. 
 
117 
 
179. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway 
in human disease. Am J Pathol. 2008;173:2–13. 
 
180. Prado Spalm F. H., Vera M. S., Dibo M. J., Simón M. V., Politi L. E., Rotstein N. P. 
(2018). Ceramide induces the death of retina photoreceptors through activation of 
parthanatos. Mol. Neurobiol. 10.1007/s12035-018-1402-4. 
 
181. Kim JH, Kim J, Roh J, Park CS, Seoh JY, Hwang ES. Reactive oxygen species-
induced parthanatos of immunocytes by human cytomegalovirus-associated 
substance. Microbiol Immunol. 2018;62(4):229–242. doi:10.1111/1348-0421.12575. 
 
182. Wen JJ, Yin YW, Garg NJ. PARP1 depletion improves mitochondrial and heart 
function in Chagas disease: Effects on POLG dependent mtDNA maintenance. PLoS 
Pathog. 2018;14(5):e1007065. Published 2018 May 31. 
doi:10.1371/journal.ppat.1007065. 
 
183. Fuyu Cheng, Wei Yuan, Mengfei Cao, Rui Chen, Xiuli Wu, and Jinchuan Yan. 
Cyclophilin A Protects Cardiomyocytes against Hypoxia/Reoxygenation-Induced 
Apoptosis via the AKT/Nox2 Pathway. Oxidative Medicine and Cellular Longevity, vol. 
2019, Article ID 2717986, 11 pages, 2019. https://doi.org/10.1155/2019/2717986. 
 
184. Nighoghossian N, Ovize M, Mewton N, Ong E, Cho TH. Cyclosporine A, a potential 
therapy of ischemic reperfusion injury. A common history for heart and 
brain. Cerebrovasc Dis. 2016;42:309. doi: 10.1159/000446850. 
 
185. Schneider, M. D. (2005). Cyclophilin D: Knocking On Deaths Door. Science 
Signaling,2005(287). 
 
186. Matsumoto, S., Friberg, H., Ferrand-Drake, M., & Wieloch, T. (1999). Blockade of 
the Mitochondrial Permeability Transition Pore Diminishes Infarct Size in the Rat after 
Transient Middle Cerebral Artery Occlusion. Journal of Cerebral Blood Flow & 
Metabolism, 19(7), 736– 741. https://doi.org/10.1097/00004647-199907000-00002. 
 
187. Waldmeier P.C., Zimmermann K., Qian T., Tintelnot-Blomley M., Lemasters J.J. 
Cyclophilin D as a drug target. Curr. Med. Chem. 2003;10:1485–1506. doi: 
10.2174/0929867033457160. 
 
188. Marc Fransen, Cyclophilin D: a therapeutic target to counteract reactive oxygen 
species–mediated damage in neurodegenerative disease?, Brain, Volume 135, Issue 12, 
December 2012, Pages 3525–3526, https://doi.org/10.1093/brain/aws304. 
 
189. Rao VK, Carlson EA, Yan SS. Mitochondrial permeability transition pore is a 
potential drug target for neurodegeneration. Biochim Biophys Acta. 2014;1842(8):1267–
1272. doi:10.1016/j.bbadis.2013.09.003. 
118 
 
 
190. Warne J, Pryce G, Hill JM, et al. Selective Inhibition of the Mitochondrial 
Permeability Transition Pore Protects against Neurodegeneration in Experimental 
Multiple Sclerosis. J Biol Chem. 2016;291(9):4356–4373. doi:10.1074/jbc.M115.700385. 
 
191. Garbaisz D, Turoczi Z, Aranyi P, Fulop A, Rosero O, Hermesz E, et al. (2014) 
Attenuation of Skeletal Muscle and Renal Injury to the Lower Limb following Ischemia-
Reperfusion Using mPTP Inhibitor NIM-811. PLoS ONE 9(6): e101067. 
https://doi.org/10.1371/journal.pone.0101067. 
 
192. Theruvath TP, Snoddy MC, Zhong Z, Lemasters JJ. Mitochondrial permeability 
transition in liver ischemia and reperfusion: role of c-Jun N-terminal kinase 
2. Transplantation. 2008;85(10):1500–1504. doi:10.1097/TP.0b013e31816fefb5. 
 
193. Tran DT, Esckilsen S, Mulligan J, Mehrotra S, Atkinson C, Nadig SN. Impact of 
Mitochondrial Permeability on Endothelial Cell Immunogenicity in 
Transplantation. Transplantation. 2018;102(6):935–944. 
doi:10.1097/TP.0000000000002163. 
 
194. Weinlich R, Oberst A, Beere HM, Green DR. Necroptosis in development, 
inflammation and disease. Nat Rev Mol Cell Biol. 2017;18:127–136. doi: 
10.1038/nrm.2016.149. 
 
195. Dhuriya, Y.K., Sharma, D. Necroptosis: a regulated inflammatory mode of cell 
death. J Neuroinflammation 15, 199 (2018) doi:10.1186/s12974-018-1235-0. 
 
196. Newton K, Manning G. Necroptosis and inflammation. Annu Rev Biochem. 
(2016) 85:743–63. 10.1146/annurev-biochem-060815-014830. 
 
197. Degterev A, Maki JL, Yuan J. Activity and specificity of necrostatin-1, small-
molecule inhibitor of RIP1 kinase. Cell Death Differ. 2013;20(2):366. 
doi:10.1038/cdd.2012.133. 
 
198. Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human 
diseases. Proc Natl Acad Sci U S A. 2019;116(20):9714–9722. 
doi:10.1073/pnas.1901179116. 
 
199. Takahashi N, Duprez L, Grootjans S, et al. Necrostatin-1 analogues: critical issues on 
the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 
2012;3(11):e437. Published 2012 Nov 29. doi:10.1038/cddis.2012.176. 
 
200. Linkermann A, Brasen JH, De Zen F, et al. Dichotomy between RIP1‐ and RIP3‐
mediated necroptosis in tumor necrosis factor alpha‐induced shock. Mol 
Med. 2012; 18: 577–586. 
119 
 
 
201.  Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death 
with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112–119. 
doi:10.1038/nchembio711. 
 
202. Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific 
cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313–321. 
doi:10.1038/nchembio.83. 
 
203. Teng X., Degterev A., Jagtap P., Xing X., Choi S., Denu R., Yuan J., Cuny G.D. 
Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med. Chem 
Lett. 2005;15:5039–5044. doi: 10.1016/j.bmcl.2005.07.077. 
 
204. Berger SB, Harris P, Nagilla R, et al. Characterization of GSK'963: a structurally 
distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015;1:15009. 
Published 2015 Jul 27. doi:10.1038/cddiscovery.2015.9. 
 
205. Harris PA, et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) 
kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory 
diseases. J. Med. Chem. 2017;60:1247–1261. doi: 10.1021/acs.jmedchem.6b01751. 
 
206. Hou J, Ju J, Zhang Z, et al. Discovery of potent necroptosis inhibitors targeting 
RIPK1 kinase activity for the treatment of inflammatory disorder and cancer 
metastasis. Cell Death Dis. 2019;10(7):493. Published 2019 Jun 24. doi:10.1038/s41419-
019-1735-6. 
 
207. Chen T., Pan H., Li J., Xu H., Jin H., Qian C., et al. (2018). Inhibiting of RIPK3 
attenuates early brain injury following subarachnoid hemorrhage: possibly through 
alleviating necroptosis. Biomed. Pharmacother. 107, 563–570. 
10.1016/j.biopha.2018.08.056. 
 
208. Mandal P, Berger SB, Pillay S, et al. RIP3 induces apoptosis independent of 
pronecrotic kinase activity. Mol Cell. 2014;56(4):481–495. 
doi:10.1016/j.molcel.2014.10.021. 
 
209. Sun L, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling 
downstream of RIP3 kinase. Cell. 2012;148:213–227. doi: 10.1016/j.cell.2011.11.031. 
 
210. Dong W, Zhang M, Zhu Y, et al. Protective effect of NSA on intestinal epithelial 
cells in a necroptosis model. Oncotarget. 2017;8(49):86726–86735. Published 2017 Sep 
30. doi:10.18632/oncotarget.21418. 
 
211. Tedesco D, Haragsim L. Cyclosporine: a review. J Transplant. 2012;2012:230386. 
doi:10.1155/2012/230386. 
120 
 
212. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. 
Improved graft survival after renal transplantation in the United States, 1988 to 1996. The 
New England Journal of Medicine. 2000;342(9):605–612. 
 
213. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin 
inhibitors avoidance in renal transplantation. Transplantation. 2001;71(9):1282–1287. 
 
214. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors 
in renal transplantation: a randomized trial comparing sirolimus and 
tacrolimus. American Journal of Transplantation. 2006;6(3):514–522. 
 
215. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate 
mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR 
study. American Journal of Transplantation. 2007;7(3):560–570. 
 
216. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin 
inhibitors in renal transplantation. The New England Journal of 
Medicine. 2007;357(25):2562–2575. 
 
217. Baroja-Mazo A, Revilla-Nuin B, Ramírez P, Pons JA. Immunosuppressive potency of 
mechanistic target of rapamycin inhibitors in solid-organ transplantation. World J 
Transplant. 2016;6(1):183–192. doi:10.5500/wjt.v6.i1.183. 
 
218. Guibert EE, Petrenko AY, Balaban CL, Somov AY, Rodriguez JV, Fuller BJ. Organ 
Preservation: Current Concepts and New Strategies for the Next Decade. Transfus Med 
Hemother. 2011;38(2):125–142. doi:10.1159/000327033. 
 
219. Hameed AM, Hawthorne WJ, Pleass HC. Advances in organ preservation for 
transplantation. ANZ J Surg. 2017;87(12):976–980. 
 
220. Van Raemdonck D, Neyrinck A, Rega F, et al. Machine perfusion in organ 
transplantation: a tool for ex-vivo graft conditioning with mesenchymal stem cells? Curr 
Opin Organ Transplant. 2013;18:24-33. 10.1097/MOT.0b013e32835c494f. 
 
221. Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, 
Abdurakhmanov D, Van Kính N, Calistru P, Heo J, et al. ESSENTIAL II Study Group 
(2015) Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in 
treatment-naive patients with chronic HCV genotype 1 infection (ESSENTIAL 
II). Aliment Pharmacol Ther. 42:829–844. 
 
222. Stanciu C, Trifan A, Muzica C, Sfarti C. (2019) Efficacy and safety of alisporivir for 
the treatment of hepatitis C infection. Expert Opin Pharmacother. 20:379–384. 
 
121 
 
223. Faustman DL, Davis M. TNF Receptor 2 and Disease: Autoimmunity and 
Regenerative Medicine. Front Immunol. 2013;4:478. Published 2013 Dec 23. 
doi:10.3389/fimmu.2013.00478. 
 
224. Pimentel-Muinos FX, Seed B. Regulated commitment of TNF receptor signaling: a 
molecular switch for death or activation. Immunity. (1999) 11:783–9310.1016/S1074-
7613(00)80152-1. 
 
225. Ando D, Inoue M, Kamada H, et al. Creation of mouse TNFR2-selective agonistic 
TNF mutants using a phage display technique. Biochem Biophys Rep. 2016;7:309–315. 
Published 2016 Jun 8. doi:10.1016/j.bbrep.2016.06.008. 
 
226. Atretkhany KN, Mufazalov IA, Dunst J, et al. Intrinsic TNFR2 signaling in T 
regulatory cells provides protection in CNS autoimmunity. Proc Natl Acad Sci USA. 
2018;115(51):13051–13056. doi:10.1073/pnas.1807499115. 
 
227. Ameloot P, et al. Identification of tumor necrosis factor (TNF) amino acids crucial for 
binding to the murine p75 TNF receptor and construction of receptor-selective mutants. J 
Biol Chem. 2001;276:37426–37430.
122 
 
CURRICULUM VITAE 
 
Name: 
 
Adnan Qamar 
 
Post-secondary 
Education and 
Degrees: 
 
2017 – Present: MSc Pathology & Laboratory Medicine 
University of Western Ontario – Canada 
 
2014: ECFMG Certification 
Educational Commission for Foreign Medical Graduates – USA  
 
2012: Bachelor of Medicine; Bachelor of Surgery 
University of Health Sciences – Pakistan 
 
Publications: 
Yau M., Khattab A., Qamar A., et al. (2018). Congenital Adrenal Hyperplasia. BMJ Best 
Practice, [http://bestpractice.bmj.com/topics/en-us/699]. 
 
Khattab A., Yau M., Qamar A., et al. (2017). Long term outcomes in 46, XX adult patients 
with congenital adrenal hyperplasia reared as males. The Journal of Steroid Biochemistry and 
Molecular Biology, Volume 165, Part A, p.12-17. 
 
Conferences: 
 
ABSTRACT TITLE: Mechanism of Mitochondria-Regulated Necroptosis in Heart Graft 
Ischemia-Reperfusion Injury and Transplant Rejection – Adnan Qamar, Patrick McLeod, Jifu 
Jiang, Xuyan Huang, Anthony M Jevnikar and Zhu-Xu Zhang. 
• American Transplant Congress 2019 – Boston, MA 
• Medical Resident Research Day 2019 – London, ON 
• London Health Research Day 2019 – London, ON 
• Pathology and Laboratory Medicine Research Day 2019 – London, ON 
• Medical Resident Research Day 2018 – London, ON 
• Pathology and Laboratory Medicine Research Day 2018 – London, ON 
 
123 
 
 
Platform Presentations: 
 
Mitochondrial Permeability Regulates Heart Graft Ischemia-Reperfusion Injury and Allograft 
Rejection. Canadian Society of Transplantation 2019 Annual Scientific Meeting, Oct 18th, 
2019, Banff, AB.  
